At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the June 2026 edition.

The IMF team of medical editors has provided overviews of key studies. Yet, we encourage you to visit the actual articles in the journals for full details and to increase your understanding. Check the IMF Newsroom monthly for updates like this one.

In the Journals (Key Myeloma Research in June 2026)

"Site-Specific Profiling of Monoclonal IgG N-Glycosylation Reveals Dynamic Sialylation Changes Associated with Multiple Myeloma"

Source

Zhao R, Si X, Fu W, Song Y, Zhao J, Zhang R. Site-Specific Profiling of Monoclonal IgG N-Glycosylation Reveals Dynamic Sialylation Changes Associated with Multiple Myeloma. J Proteome Res. 2026 Jun 1. doi: 10.1021/acs.jproteome.5c01182..  

Overview

Researchers developed a new mass spectrometry–based method to analyze sugar molecules (glycans) attached to M-proteins in patients with MGUS and multiple myeloma. The study aimed to determine whether specific glycosylation patterns could serve as biomarkers for diagnosing myeloma and monitoring how patients respond to treatment.

"Hyaluronic acid-based supramolecular peptide-drug conjugate prodrug nanosystems for precise multiple myeloma therapy"

Source

Xiangyu Deng, Qili Huang, Li Cao, Ran Luo, Wenyan Wang, Hongzhong Chen, Chendi Ding, Lina Su, Lin Mei, Hyaluronic acid-based supramolecular peptide-drug conjugate prodrug nanosystems for precise multiple myeloma therapy, Carbohydrate Polymers, Volume 381, 2026, 125159, ISSN 0144-8617, https://doi.org/10.1016/j.carbpol.2026.125159. June 1, 2026.   

Overview

Researchers developed an experimental nanoparticle drug delivery system designed to improve the effectiveness of melphalan and dexamethasone in multiple myeloma. The goal was to deliver both drugs together at a fixed ratio directly to myeloma cells, increasing antitumor activity while reducing systemic toxicity and damage to healthy tissues.

"Preapheresis clinical patient profiles predict patient’s manufacturing fitness and efficacy with idecabtagene vicleucel"

Source

Julie Rytlewski, Doris K. Hansen, Lauren C. Peres, Jaymes Fuller, David R. Mertz, Fan Wu, Gabriel de Avila, Salomon Manier, Meghan Menges, Kayla Reid, Salvatore Corallo, Luis A. Cuadrado Delgado, Frederick L. Locke, Timothy B. Campbell, Ciara L. Freeman; Preapheresis clinical patient profiles predict patient’s manufacturing fitness and efficacy with idecabtagene vicleucel. Blood Immunology & Cellular Therapy 2026; 2 (2): 100036. doi: https://doi.org/10.1016/j.bict.2026.100036  June 1, 2026. 

Overview

Researchers investigated how a patient's health before CAR T-cell manufacturing affects the quality of idecabtagene vicleucel (ide-cel) and treatment outcomes in relapsed or refractory multiple myeloma. The study found that patients with higher disease burden, greater inflammation, and poorer immune health before cell collection were more likely to produce lower-quality CAR T-cell products and experienced lower response rates and shorter progression-free survival after treatment.
 

"Clinical-grade armored BCMA CAR T cells overcome TGF-β–mediated immunosuppression in multiple myeloma"

Source

Deepak Parashar, Katie Palen, Ansul Sharma, Swadha Pandey, Tyce Kearl, Peirong Hu, Peiman Hematti, Sabari Venniyil Radhakrishnan, Fumou Sun, Siegfried Janz, Bryon Johnson, Dina Schneider, Nirav Shah, Binod Dhakal; Clinical-grade armored BCMA CAR T cells overcome TGF-β–mediated immunosuppression in multiple myeloma. Blood Immunology & Cellular Therapy 2026; 2 (2): 100048. doi: https://doi.org/10.1016/j.bict.2026.100048  June 1, 2026. 

Overview

Researchers developed an experimental BCMA-targeted CAR T-cell therapy designed to resist the immunosuppressive effects of TGF-β, a protein in the bone marrow that can limit CAR T-cell activity and contribute to relapse in multiple myeloma. In preclinical studies, these engineered "armored" CAR T cells showed enhanced persistence, stronger antitumor activity, and better protection against relapse than conventional BCMA CAR T cells, supporting further clinical development.
 

"Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of Therapy"

Source

Doris K. Hansen, Maria Victoria Mateos, Luciano J. Costa, Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of Therapy, Blood Advances, 2026, ISSN 2473-9529, https://doi.org/10.1182/bloodadvances.2026019699. June 2, 2026.  

Overview

This review examines how BCMA-targeted therapies—including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates—are changing the treatment of multiple myeloma at first relapse. The authors compare recent phase 3 clinical trial data and discuss how factors such as patient characteristics, prior treatments, access to therapy, and logistical considerations can help guide treatment selection in real-world practice.
 

"Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma"

Source

Susan Bal, Myo Htut, Omar Nadeem, Larry D. Anderson, Tara Gregory, Mehmet Kocoglu, Adriana C Rossi, Tom G Martin, Daniel Nathan Egan, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Shaoyi Li, Lisa M Kelly, Naomey Sarkis, Safiyyah Ziyad, Kristina M Jordahl, Wei-Ming Kao, Allison June Kaeding, Michael R. Burgess, Jesus G Berdeja; Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma. Blood 2026; blood.2025030750. doi: https://doi.org/10.1182/blood.2025030750  June 2, 2026.   

Overview

Researchers evaluated arlocabtagene autoleucel (arlo-cel), an investigational GPRC5D-targeted CAR T-cell therapy, in patients with heavily pretreated relapsed or refractory multiple myeloma, including many who had previously received BCMA-targeted therapy. The phase 1 study found that arlo-cel produced deep and durable responses with a manageable safety profile, supporting its continued development as a treatment option for patients whose disease has progressed after multiple prior therapies.
 

"Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis"

Source

Berning, P., Maulhardt, M., Boyadzhiev, H. et al. Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis. Blood Cancer J. 16, 88 (2026). https://doi.org/10.1038/s41408-026-01531-w  June 2, 2026. 

Overview

Researchers compared the safety and effectiveness of BCMA-directed CAR T-cell therapy in patients with relapsed or refractory multiple myeloma who were younger than 70 years with those aged 70 years and older. Despite having more frailty and comorbidities, older patients had response rates, progression-free survival, overall survival, and treatment-related side effects that were similar to those of younger patients, suggesting that age alone should not determine eligibility for CAR T-cell therapy. 

 

"Reporting of primary endpoint and associated spin in randomized myeloma trials"

Source

Mitch Singstock, Abul Hasan Shadali Abdul Khader, Cole Wayant, Mackenzie Lemieux, Maria Mainou, Ghulam Rehman Mohyuddin, Reporting of primary endpoint and associated spin in randomized myeloma trials, The Oncologist, 2026;, oyag221, https://doi.org/10.1093/oncolo/oyag221  June 2, 2026. 

Overview

Researchers evaluated how randomized clinical trials in multiple myeloma report their results, focusing on whether study conclusions accurately reflected the primary endpoint or overstated the findings through "spin." The analysis found that about one-third of trials contained reporting practices that could mislead readers, most often by emphasizing positive secondary or subgroup results when the primary endpoint was not met, highlighting the need for more transparent reporting.

 

"Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma"

Source

H.Xu, W.Wu, Y.Jiang, J.Wang, Y.Zhai, and Z.Zhao, “Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma,” Cancer Medicine15, no. 6 (2026): e71985, https://doi.org/10.1002/cam4.71985. 

Overview

Researchers investigated whether blocking p300, a protein that regulates gene activity through epigenetic changes, could slow the growth of multiple myeloma cells. The study found that the experimental p300 inhibitor A485 suppressed key myeloma-driving genes and worked synergistically with the XPO1 inhibitor eltanexor in laboratory and animal models, suggesting a potential new combination strategy for treating multiple myeloma.

 

"Biological Drivers of IMiD-Induced Peripheral Neuropathy in Multiple Myeloma"

Source

S. A. Beer, R. Houlston, and M. F. Kaiser, “Biological Drivers of IMiD-Induced Peripheral Neuropathy in Multiple Myeloma.” eJHaem7, no. 3 (2026): e70323. https://doi.org/10.1002/jha2.70323  June 2, 2026. 

Overview

This review examines why immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide can cause peripheral neuropathy in patients with multiple myeloma. The authors summarize current evidence on the biological and genetic mechanisms underlying this side effect and identify research priorities that could lead to better strategies for predicting, preventing, and treating IMiD-induced peripheral neuropathy.

 

"Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer"

Source

Jónas A Aðalsteinsson, Gauti Kjartan Gislasson, Styrmir Hallsson, Kelley Sharp, Sigrún Thorsteinsdóttir, Sæmundur Rögnvaldsson, Ásdís R Þórðardóttir, Brynjar Viðarsson, Páll T Önundarson, Bjarni A Agnarsson, Margrét Sigurðardóttir, Ingunn Þorsteinsdóttir, Ísleifur Ólafsson, Elías Eyþórsson, Ásbjörn Jónsson, Andri Ólafsson, Jón Kristinn Sigurðsson, Jon Gunnlaugur Jonasson, Ola Landgren, Malin Hultcrantz, Brian G M Durie, Stephen Harding, Thorvardur Jon Love, Sigurdur Yngvi Kristinsson, Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer, British Journal of Dermatology, 2026;, ljag119, https://doi.org/10.1093/bjd/ljag119 June 2, 2026.  

Overview

Researchers investigated whether people with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing skin cancer. Using a large nationwide cancer registry, the study aimed to determine whether MGUS itself is associated with skin cancer risk, independent of progression to multiple myeloma.

 

"Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention"

Source

Karie Feldman, Hong Li, Diana Basali, Faiz Anwer, Kimberly Bell, Beth Faiman, Raymond D. Jackson, Sandra Mazzoni, Kayona Moore, Natasha Patel, Shahzad Raza, Jason Valent, Heather McKee. Hurwitz; Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention. Cancer Research Communications 2026; https://doi.org/10.1158/2767-9764.CRC-26-0056 June 3, 2026. 

Overview

Researchers developed and evaluated the first community-based multiple myeloma screening and education program for Black adults aged 50 and older. The program improved participants' understanding of multiple myeloma and MGUS, identified MGUS in 11% of those screened, and demonstrated that community education and screening may support earlier detection and more informed healthcare decisions.

 

"Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma"

Source

Rafael R. Canevarolo, Praneeth Reddy Sudalagunta, Mark B. Meads, Maria Silva, Xiaohong Zhao, Dario Magaletti, Raghunandan Reddy Alugubelli, Gabriel DeAvila, Daniel DeAvila, Erez Persi, Francesco Maura, Elissa T. Bell, Ryan T. Bishop, Christopher L. Cubitt, Samer S. Sansil, Wei Zhang, Jamie K. Teer, Mingxiang Teng, Sean J. Yoder, Erin M. Siegel, Bijal D. Shah, Taiga Nishihori, Lori Hazlehurst, Conor C. Lynch, Ola Landgren, Oliver Hampton, Robert A. Gatenby, Daniel M. Sullivan, Jason Brayer, William Dalton, John L. Cleveland, Melissa Alsina, Rachid Baz, Kenneth H. Shain, Ariosto S. Silva; Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma. Cancer Res 2026; https://doi.org/10.1158/0008-5472.CAN-26-1082 June 3, 2026. 

Overview

Researchers analyzed nearly 900 patient samples spanning MGUS, smoldering multiple myeloma, newly diagnosed myeloma, and advanced relapsed disease to understand how multiple myeloma evolves and becomes resistant to treatment. The study found that changes in gene regulation driven by epigenetic remodeling play a central role in disease progression and therapy resistance, identifying epigenetic plasticity as a potential target for future myeloma therapies.

 

"Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia"

Source

D. G.Packard, S. K.Kumar, A.Dispenzieri, et al., “Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia,” American Journal of Hematology (2026): 1–9, https://doi.org/10.1002/ajh.70400.  June 3, 2026. 

Overview

Researchers examined outcomes after first relapse in patients with primary plasma cell leukemia (pPCL), a rare and aggressive form of plasma cell cancer. The study found that responses became shorter with each successive line of therapy, but patients with t(11;14) disease treated with BCL-2–targeted therapy and those who received BCMA-directed CAR T-cell therapy experienced more durable disease control, identifying two promising treatment approaches for relapsed pPCL.

 

"PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma"

Source

Anaïs Schavgoulidze, Jian Cui, Jessica Encinas, Vanessa Katia Favasuli, Srikanth Talluri, Sabrina Mahéo, Chloe Cerutti, Masood A Shammas, Daniel Primo, Carmen Vicente, Marta Larrayoz, Jose A Martínez-Climent, Kenneth C. Anderson, Anil Aktas Samur, Mehmet K. Samur, Herve Avet-Loiseau, Jill Corre, Nikhil C. Munshi, Mariateresa Fulciniti; PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma. Blood 2026; blood.2026033819. doi: https://doi.org/10.1182/blood.2026033819 June 3, 2026.  

Overview

Researchers identified PKMYT1 as a potential treatment target for patients with multiple myeloma carrying deletion 17p [del(17p)] or TP53-deficient disease, a high-risk genetic subtype associated with poor outcomes. In laboratory and animal studies, blocking PKMYT1 with the experimental drug RP-6306 selectively killed del(17p) myeloma cells while largely sparing healthy cells and extended survival, supporting further development of this biomarker-guided treatment approach.

 

"Engineering a TACI×CD3 Bispecific Antibody to Redirect T Cells Against Multiple Myeloma"

Source

Minchuan Zhang, Wai Fook Leong, Jianxin Huo, Eve Zi Xian Ngoh, Hanping Loh, Qingfeng Chen, Sabrina Hui Min Toh, Sanjay de Mel, Melissa GM Ooi, Cinnie Yentia Soekojo, Wee Joo Chng, Yuansheng Yang, Kong-Peng Lam, Shengli Xu; Engineering a TACI×CD3 Bispecific Antibody to Redirect T Cells Against Multiple Myeloma. Blood Adv 2026; bloodadvances.2025018210. doi: https://doi.org/10.1182/bloodadvances.2025018210 June 3, 2026   

Overview

Researchers developed an experimental bispecific antibody that targets **TACI**, a protein found on multiple myeloma cells, as a potential treatment for patients whose disease has become resistant to BCMA-targeted therapies. In laboratory studies, the TACI × CD3 bispecific antibody activated T cells and effectively killed myeloma cells, including cells with reduced BCMA expression, suggesting a possible strategy for overcoming resistance to BCMA-directed immunotherapy.

 

"Interpreting [18F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial"

Source

Sachpekidis, C., Hajiyianni, M., Wennmann, M. et al. Interpreting [18F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial. Eur J Nucl Med Mol Imaging (2026). https://doi.org/10.1007/s00259-026-07962-8 June 3, 2026. 

Overview

Researchers examined whether new FDG-avid fractures seen on PET/CT scans after induction therapy represent active multiple myeloma or normal bone healing. In a small group of patients who had achieved complete metabolic remission, these fractures were not associated with disease relapse during follow-up, suggesting they most likely reflected healing bone rather than persistent myeloma.

 

"Harnessing CAR-NK cells against multiple myeloma: current landscape and future direction"

Source

Anvari, S., Naghinezhad, J., Shokati, A. et al. Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions. Mol Biol Rep 53, 885 (2026). https://doi.org/10.1007/s11033-026-11990-w June 4, 2026.  

Overview

This review examines the current state of CAR-engineered natural killer (CAR-NK) cell therapy for multiple myeloma and the challenges that must be addressed before it can become a widely available treatment. The authors discuss advances in CAR-NK cell design, biomarker-guided patient selection, and scalable manufacturing strategies that could improve the safety, effectiveness, and accessibility of this emerging immunotherapy.
 

"Identification and validation of prognostic genes related to centrosome amplification in multiple myeloma"

Source

Liao P, Tan J, Zeng L, Lai P, Wei X. 2026. Identification and validation of prognostic genes related to centrosome amplification in multiple myeloma. PeerJ 14:e21283 https://doi.org/10.7717/peerj.21283  June 4, 2026. 

Overview

Researchers identified six genes linked to centrosome amplification that may help predict outcomes in multiple myeloma and used them to develop a prognostic risk model. The model was associated with survival, immune cell infiltration, and sensitivity to certain therapies, suggesting it could help identify patients at higher risk and guide future treatment strategies. 
 

"CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation"

Source

Simone A. Minnie, Kenneth Ho, Julie R. Boiko, Rachael C. Adams, Kathleen S. Ensbey, Nicole S. Nemychenkov, Samuel R. W. Legg, Christine R. Schmidt, Melissa L. Comstock, Justina M. Lyons, Tomoko Sekiguchi, Motoko Koyama, Andrew Spencer, Damian J. Green, Geoffrey R. Hill; CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation. Blood 2026; 147 (23): 2786–2792. doi: https://doi.org/10.1182/blood.2025030207 June 4, 2026.  

Overview

Researchers identified a population of immunosuppressive macrophages in the bone marrow that was associated with relapse after autologous stem cell transplantation (ASCT) in multiple myeloma. In preclinical models, combining CSF-1R inhibition with lenalidomide maintenance depleted these macrophages, enhanced antimyeloma immune responses, and prolonged survival, suggesting a potential strategy to reduce the risk of relapse after ASCT.
 

"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study"

Source

Robert Z. Orlowski, Meletios A. Dimopoulos, Xavier Leleu, Thierry Facon, Tadao Ishida, Roman Hájek, Ivan Špička, Joanna Romejko-Jarosinska, Vladimir Vorobyev, Britta Besemer, Sevgi Kalayoğlu Beşışık, Pawel Robak, Tomas Jelinek, Hartmut Goldschmidt, Thomas Martin, Mohamad Mohty, Sandrine Macé, Ercem Kodas, Christina Tekle, Andrea T. Shafer, Philippe Moreau; Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study. Blood 2026; 147 (23): 2760–2769. doi: https://doi.org/10.1182/blood.2025030120  June 4, 2026.  

Overview

Researchers analyzed minimal residual disease (MRD) outcomes from the phase 3 IMROZ trial to determine how sustained MRD negativity affects long-term outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma. The study found that Isa-VRd followed by Isa-Rd produced deeper and more durable MRD-negative responses than VRd followed by Rd, supporting MRD monitoring as a tool for guiding treatment decisions and reinforcing Isa-VRd as a frontline standard of care for transplant-ineligible patients.
 

"A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma"

Source

Li, R., Huang, L., Hao, Z. et al. A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma. Discov Onc (2026). https://doi.org/10.1007/s12672-026-05344-y June 4, 2026.  

Overview

This bibliometric review examined global research trends on lenalidomide resistance in multiple myeloma over the past two decades. The analysis identified growing interest in the field and highlighted key research priorities, including combination therapies, the biological mechanisms of resistance, and strategies to overcome resistance through new drugs and targeted treatment approaches.

 

"Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement"

Source

Jimenez-Mira C, Tovar N, Martínez-Cibrián N, González-Calle V, Albiol N, López-Muñoz N, et al. Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement. Br J Haematol. 2026;00:1–11. https://doi.org/10.1111/bjh.70586  June 4, 2026.   

Overview

Researchers evaluated the BCMA-directed CAR T-cell therapy cesnicabtagene autoleucel (ARI0002h) in patients with ultra-high-risk multiple myeloma, including those with plasma cell leukemia (PCL) or central nervous system (CNS) involvement. The therapy produced deep responses in this difficult-to-treat population, with an overall response rate of 88%, supporting further study of CAR T-cell therapy in patients who are often excluded from clinical trials.

 

"Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma"

Source

F. Carreño, M. van Noort, A. Taylor, et al., “Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma,” CPT: Pharmacometrics & Systems Pharmacology15, no. 6 (2026): e70276, https://doi.org/10.1002/psp4.70276. June 4, 2026. 

Overview

Researchers developed a computer simulation model to predict how different dosing schedules of belantamab mafodotin affect treatment response and eye-related side effects in patients with relapsed or refractory multiple myeloma. The model accurately reflected outcomes from the phase 3 DREAMM-7 and DREAMM-8 trials and suggested that adjusting the dosing schedule after the first treatment may reduce eye toxicity while maintaining the drug's effectiveness.

 

"Impact of Treatment Sequencing with CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model"

Source

Jodi Lipof, Brian Bloudek, Avik Ray, Jie Ting, Ken Hasegawa, Cynthia Gong, Troy Williams, Scott Ramsey, Ajai Chari, Impact of Treatment Sequencing with CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.05.014. June 5, 2026. 

Overview

Researchers used a simulation model to compare two treatment sequences for patients with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy: CAR T-cell therapy followed by a bispecific antibody versus a bispecific antibody followed by CAR T-cell therapy. The model predicted that starting with CAR T-cell therapy would result in longer progression-free and overall survival while reducing overall healthcare costs, supporting CAR T as the preferred first treatment in this setting.

 

"Impact of Treatment Sequencing with CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model"

Source

Jodi Lipof, Brian Bloudek, Avik Ray, Jie Ting, Ken Hasegawa, Cynthia Gong, Troy Williams, Scott Ramsey, Ajai Chari, Impact of Treatment Sequencing with CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.05.014. June 5, 2026. 

Overview

Researchers used a computer simulation to evaluate the best sequence for CAR T-cell therapy and bispecific antibodies in patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy. The model predicted that giving CAR T-cell therapy before a bispecific antibody could substantially prolong progression-free and overall survival while lowering long-term treatment costs compared with using a bispecific antibody first.

 

"D-VRD induction and autologous transplant in patients ≥70 years"

Source

Pasvolsky, O., Marcoux, C., Milton, D.R. et al. D-VRD induction and autologous transplant in patients ≥70 years. Blood Cancer J. 16, 91 (2026). https://doi.org/10.1038/s41408-026-01522-x  June 5, 2026. 

Overview

Researchers evaluated the safety and effectiveness of daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) followed by autologous stem cell transplantation (ASCT) in patients aged 70 years and older with newly diagnosed multiple myeloma. The study found that carefully selected older adults achieved response rates, progression-free survival, and overall survival comparable to those of younger patients, supporting the use of D-VRd and ASCT based on fitness rather than age alone.

 

"Zero echo time MRI with deep learning reconstruction and chemical shift correction for detecting osteolytic myeloma lesions"

Source

Lepot, D., Chabot, C., Duchêne, G. et al. Zero echo time MRI with deep learning reconstruction and chemical shift correction for detecting osteolytic myeloma lesions. Eur Radiol Exp 10, 81 (2026). https://doi.org/10.1186/s41747-026-00734-x June 5, 2026. 

Overview

Researchers evaluated an artificial intelligence–enhanced MRI technique to determine whether it could detect bone lesions from multiple myeloma more accurately than standard MRI sequences. The study found that the deep learning–reconstructed zero echo time MRI (ZTE-DLCSC) sequence detected more osteolytic lesions with greater accuracy and consistency, supporting its potential as a radiation-free alternative for assessing myeloma-related bone disease.

 

"Where Is the ‘Oma’ in Multiple Myeloma? Origins and Limitations of some Myeloma-Related Terminology"

Source

J. Thachil and D. P. Steensma, “Where Is the ‘Oma’ in Multiple Myeloma? Origins and Limitations of some Myeloma-Related Terminology.” eJHaem7, no. 3 (2026): e70326. https://doi.org/10.1002/jha2.70326  June 6, 2026. 

Overview

This review examines the origins and evolution of the terminology used in multiple myeloma, including terms such as myeloma, paraprotein, immunoglobulins, kappa and lambda light chains, and plasma cells. The authors explain how these terms developed over time, discuss their historical context and limitations, and consider whether some longstanding terminology still accurately reflects current understanding of the disease.

 

"Cost-effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma"

Source

Irfan, S., Jamil, M.A. and Abid, M.B. (2026), Cost-effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma. Br J Haematol. https://doi.org/10.1111/bjh.70607  June 7, 2026.  

Overview

Researchers compared the projected long-term value of teclistamab plus daratumumab with ciltacabtagene autoleucel (cilta-cel) for patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. Although the model predicted longer progression-free survival with teclistamab plus daratumumab, the high cost of continuous treatment made it less cost-effective than the one-time CAR T-cell therapy at current pricing, highlighting the potential value of fixed-duration bispecific antibody treatment.

 

"Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma"

Source

Vega, G., Morillo, D., Riedhammer, C., Smits, F., Bag, A., Julian, K., Gomis, N.T., Gaisan, C.M., Bermudez, M.A., Shah, M.R., Mohyuddin, G.R., Dhakal, B., Rasche, L., Schinke, C., D'Souza, A., Szabo, A., van de Donk, N.W.C.J., Chakraborty, R. and Mohan, M. (2026), Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. HemaSphere, 10: e70396. https://doi.org/10.1002/hem3.70396 June 7, 2026.  

Overview

Researchers evaluated whether some patients with relapsed or refractory multiple myeloma can safely stop bispecific antibody (bsAb) therapy after achieving a deep response. The study found that many patients maintained long-lasting, treatment-free remissions after discontinuing therapy, while infection risk gradually declined and immune function recovered over time, supporting further research into fixed-duration bsAb treatment.

 

"Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry"

Source

Lim, K.J.C., Ashrafi, E., Wellard, C., Moore, E.M., Gration, B., Augustson, B., Mollee, P., Zhang, J., Doo, N.W., Dun, K., Cooke, R., Ringkowski, S., Bryant, A., McCaughan, G., Wood, E., McQuilten, Z., Ho, P.J., Quach, H. and Spencer, A. (2026), Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry. Br J Haematol. https://doi.org/10.1111/bjh.70609  June 7, 2026.  

Overview

Researchers evaluated the International Myeloma Society/International Myeloma Working Group (IMS/IMWG) Consensus Genomic Staging system in a real-world cohort of newly diagnosed multiple myeloma patients. The study confirmed that the staging system identifies patients with poorer survival and a higher risk of early relapse, particularly among transplant-eligible, non-frail patients, while highlighting the need to combine genomic risk with early treatment response to better identify patients with functional high-risk disease.
 

"CD70-targeted platform for diagnosing and treating multiple myeloma"

Source

Li J, Yan H, Wang X, Zhang Y, Chen P, Feng J, et al. CD70-targeted platform for diagnosing and treating multiple myeloma. Journal for ImmunoTherapy of Cancer. 2026;14:e014058. https://doi.org/10.1136/jitc-2025-014058  June 8, 2026. 

Overview

Researchers developed a CD70-targeted theranostic platform that combines PET imaging with targeted radiotherapy for multiple myeloma. In preclinical models, the approach accurately identified CD70-positive myeloma cells and slowed tumor growth while extending survival, supporting further development of this strategy for patients with CD70-positive disease.
 

"Promoter Methylation of HOXA5 and NDRG2 in Multiple Myeloma Patients with Renal Impairment"

Source

Haroun, R.AH., Elsaid, D.S., Al-Dosoky, M.A. et al. Promoter Methylation of HOXA5 and NDRG2 in Multiple Myeloma Patients with Renal Impairment. Biochem Genet (2026). https://doi.org/10.1007/s10528-026-11401-6 June 8, 2026. 

Overview

Researchers investigated whether HOXA5 and NDRG2 promoter methylation could serve as biomarkers in multiple myeloma and help predict the risk of renal impairment, a common complication of the disease. The study found that NDRG2 promoter hypermethylation was associated with an increased risk of kidney impairment and poorer overall survival, suggesting it may be a useful biomarker for identifying patients at higher risk of renal complications.
 

"Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regressio"

Source

Ainsley Ryan Yan Bin Lee, Hon Jen Wong, Chi Ching Lim, Sanjay De Mel, Melissa Ooi, Wee Joo Chng, Yu Yang Soon, Cinnie Yentia Soekojo, Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression, Transplantation and Cellular Therapy, 2026, ISSN 2666-6367, https://doi.org/10.1016/j.jtct.2026.06.001. June 8, 2026.  

Overview

Researchers reviewed data from more than 1,800 patients to compare the effectiveness and safety of different CAR T-cell therapies for multiple myeloma, including BCMA-, GPRC5D-, and dual-targeted approaches. The analysis found that CAR T-cell therapy produced high response rates and deep remissions across multiple platforms, while GPRC5D-directed CAR T-cell therapy showed promising activity in patients whose disease had become resistant to prior BCMA-targeted treatment.
 

"Real-World Outcomes of Thromboprophylaxis With Apixaban in Patients With Newly Diagnosed Multiple Myeloma, the MyelMeXa Study"

Source

K. A. Sanchez, G. Cesarman-Maus, M. Flores-Cruz, B. Cabello, R. Espinoza, and O. E. Fernandez-Vargas, “Real-World Outcomes of Thromboprophylaxis With Apixaban in Patients With Newly Diagnosed Multiple Myeloma, the MyelMeXa Study.” eJHaem7, no. 3 (2026): e70325. https://doi.org/10.1002/jha2.70325  June 8, 2026.  

Overview

Researchers evaluated apixaban as primary blood clot prevention in patients with newly diagnosed multiple myeloma receiving treatment. The study found very low rates of clinically significant blood clots and no major bleeding events, suggesting that apixaban may be a safe and effective option for thromboprophylaxis and warrants further study in larger clinical trials.
 

"CAR T-cell Therapy for Extramedullary Multiple Myeloma: from Early Response to Durable Disease Control"

Source

Yang, Z., Zhou, M. & Xiao, Y. CAR T-cell Therapy for Extramedullary Multiple Myeloma: from Early Response to Durable Disease Control. Stem Cell Rev and Rep (2026). https://doi.org/10.1007/s12015-026-11171-z June 8, 2026. 

Overview

Researchers evaluated apixaban as primary blood clot prevention in patients with newly diagnosed multiple myeloma receiving treatment. The study found very low rates of clinically significant blood clots and no major bleeding events, suggesting that apixaban may be a safe and effective option for thromboprophylaxis and warrants further study in larger clinical trials.
 

"Relationship between early use of tocilizumab during chimeric antigen receptor T-cell therapy for multiple myeloma and cardiovascular risk and progression-free survival"

Source

Sophia Golec, Weijia Fu, Erin Moshier, Ariel Peleg, Brunna Pileggi, Adriana Rossi, Gagan Sahni, Relationship between early use of tocilizumab during chimeric antigen receptor T-cell therapy for multiple myeloma and cardiovascular risk and progression-free survival, European Heart Journal Open, Volume 6, Issue 3, May 2026, oeag097, https://doi.org/10.1093/ehjopen/oeag097  June 9, 2026. 

Overview

Researchers evaluated whether early use of tocilizumab to treat cytokine release syndrome (CRS) after CAR T-cell therapy could reduce cardiovascular complications in patients with relapsed or refractory multiple myeloma. The study found low rates of major cardiovascular adverse events without compromising progression-free or overall survival, supporting further investigation of early or preventive tocilizumab use during CAR T-cell treatment.
 

"Nanoplastics perturb extracellular vesicle-mediated communication in the in vitro and ex vivo bone marrow microenvironment of multiple myeloma"

Source

Villa Alessandro, Citro Valentina, Sauro Giulia, Ciana Paolo, Chiaramonte Raffaella, Giannandrea Domenica, Platonova Natalia, Lesma Elena, Bernardelli Clara, De Felice Beatrice, Turrini Mauro, Guidotti Francesca, Chiu Martina, Parolini Marco, Casati Lavinia, Nanoplastics perturb extracellular vesicle-mediated communication in the in vitro and ex vivo bone marrow microenvironment of multiple myeloma, Journal of Hazardous Materials, 2026, 142667, ISSN 0304-3894, https://doi.org/10.1016/j.jhazmat.2026.142667. June 9, 2026.   

Overview

Researchers investigated how nanoplastics affect communication between multiple myeloma cells and the bone marrow microenvironment. The study found that nanoplastic exposure altered the release and contents of extracellular vesicles, disrupting signaling involved in bone formation and suggesting that environmental nanoplastics may influence myeloma biology and bone disease. 

"CD20 by diagnostic flow cytometry helps discriminate monoclonal gammopathy of undetermined significance and multiple myeloma plasma cells"

Source

Lee, A.Y.S. CD20 by diagnostic flow cytometry helps discriminate monoclonal gammopathy of undetermined significance and multiple myeloma plasma cells. Discov. Immun. 3, 8 (2026). https://doi.org/10.1007/s44368-026-00026-x  June 9, 2026.  

Overview

Researchers evaluated whether flow cytometry can better distinguish MGUS from multiple myeloma by comparing the immunophenotypes of monoclonal plasma cells. The study found that CD20 expression was more commonly retained in MGUS than in multiple myeloma, suggesting that adding CD20 to routine flow cytometry panels could improve diagnostic accuracy and help differentiate precursor disease from active myeloma.

"Addressing Diagnostics Delay in Multiple Myeloma: Insights from a National Survey of Primary Care Providers"

Source

Bhrugu Yagnik, Jill Pauli, Brittany Watson, Joseph Mikhael, Addressing Diagnostics Delay in Multiple Myeloma: Insights from a National Survey of Primary Care Providers, The Journal of Applied Laboratory Medicine, 2026; jfag087, https://doi.org/10.1093/jalm/jfag087 June 9, 2026.

Overview

Researchers surveyed U.S. primary care providers to evaluate their knowledge and confidence in diagnosing multiple myeloma and related plasma cell disorders. The study found significant gaps in guideline-based testing, with fewer than one-third using the recommended combination of serum protein electrophoresis (SPEP) and serum free light chain testing, highlighting the need for better education, diagnostic tools, and specialist support to promote earlier diagnosis.

"Geriatric nutritional risk index for the prediction of venous thrombotic events in multiple myeloma"

Source

Suzuki, K., Gunji, T., Nagao, R. et al. Geriatric nutritional risk index for the prediction of venous thrombotic events in multiple myeloma. Int J Clin Oncol (2026). https://doi.org/10.1007/s10147-026-03074-3 June 9, 2026. 

Overview

Researchers evaluated whether the Geriatric Nutritional Risk Index (GNRI), a measure of nutritional status, could predict the risk of venous thromboembolism (VTE) in patients with newly diagnosed multiple myeloma. The study found that poor nutritional status was associated with a higher risk of blood clots and shorter overall survival, suggesting that the GNRI may help identify patients who need closer monitoring and supportive care.

"FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial"

Source

Bastien Jamet, Shamimeh Ahrari, Sonja Zweegman, Aurore Perrot, Cyrille Hulin, Denis Caillot, Thierry Facon, Xavier Leleu, Karim Belhadj, Emmanuel Itti, Lionel Karlin, Clément Bailly, Mark-David Levin, Monique C. Minnema, Caroline Bodet-Milin, Bart de Keizer, Jill Corre, Pieter Sonneveld, Diana Mateus, Philippe Moreau, Cyrille Touzeau, Françoise Kraeber-Bodéré, Thomas Carlier; FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial. Blood Adv 2026; 10 (11): 3787–3798. doi: https://doi.org/10.1182/bloodadvances.2025019465  June 9, 2026. 

Overview

Researchers evaluated whether metabolic tumor volume (mTMTV) measured by FDG-PET/CT at diagnosis could improve risk assessment in patients with newly diagnosed multiple myeloma receiving daratumumab-based therapy. The study found that mTMTV was a strong independent predictor of progression-free and overall survival and, when combined with the Revised International Staging System (R-ISS), improved identification of patients at higher risk of disease progression and death.

"Potential benefits and harms of screening strategies for monoclonal gammopathy of undetermined significance in the US: A simulation study"

Source

Ishfaq Ahmad, Rong Wang, Natalia Neparidze, Jane Lange, Shi-Yi Wang, Potential benefits and harms of screening strategies for monoclonal gammopathy of undetermined significance in the US: A simulation study, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.06.001. June 9, 2026.  

Overview

Researchers used a computer simulation model to evaluate the potential benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS) in the general U.S. population. The analysis found that while screening could identify multiple myeloma earlier, most people diagnosed with MGUS through screening would never develop myeloma, highlighting the importance of focusing screening efforts on individuals at high risk..

"Clinical and biological implications of TP53 abnormalities in relapsed/refractory multiple myeloma: the DEDALO study"

Source

Vittorio Montefusco, Anna Maria Cafro, Gloria Margiotta-Casaluci, Roberto Mina, Francesca Patriarca, Mattia D’Agostino, Anna Benedetta Dalla Palma, Rita Rizzi, Martina di Trani, Paola Bertazzoni, Gaetano Vaudo, Maria Teresa Petrucci, Laura Paris, Angelo Belotti, Katia Mancuso, Concetta Conticello, Carmelo Carlo-Stella, Mario Boccadoro, Clinical and biological implications of TP53 abnormalities in relapsed/refractory multiple myeloma: the DEDALO study, Clinical Lymphoma Myeloma and Leukemia, 2026,ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.05.013 June 9, 2026. 

Overview

Researchers evaluated daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma carrying deletion 17p [del(17p)], a high-risk genetic abnormality. The study confirmed the poor prognosis associated with del(17p)—especially when combined with TP53 mutations—and showed that while DPd had a manageable safety profile, patients with biallelic TP53 alterations experienced the shortest progression-free survival, underscoring the need for more effective targeted therapies.

"Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM"

Source

Surbhi Sidana, Yi Lin, Andrew J. Cowan, Paula Rodríguez-Otero, Christof Scheid, Peter J. Mueller, Connor Broussard, Peter Krengel, Yun Li, Romain Piault, Amy Corrao, Christine Ho, Krina Patel; Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM. Blood Adv 2026; 10 (11): 3769–3776. doi: https://doi.org/10.1182/bloodadvances.2025017186  June 9, 2026. 

Overview

Researchers evaluated the manufacturing performance and clinical outcomes of idecabtagene vicleucel (ide-cel), including CAR T-cell products that did not meet standard commercial release criteria but were made available through an expanded access program. The study found that ide-cel manufacturing became faster and more reliable over time, and that these out-of-specification products maintained high response rates and a safety profile consistent with commercially released ide-cel.

"Analytical validation and clinical concordance of Diazyme free light chain assays on the Cobas® platform compared with Freelite™"

Source

Masri W, Abarah W, Taileb M, Cung A, Bendaoud M. Analytical validation and clinical concordance of Diazyme free light chain assays on the Cobas® platform compared with Freelite™. Ann Biol Clin (Paris). 2026 Jun 10;84(3):0. doi: 10.1684/abc.2026.2044. Epub ahead of print.  

Overview

Researchers compared the Diazyme serum free light chain (FLC) assay with the Freelite™ assay, the test recommended by the International Myeloma Working Group (IMWG), for diagnosing and monitoring plasma cell disorders. The study found that the Diazyme assay showed strong agreement with Freelite™ and accurately measured free light chains and the κ/λ ratio, supporting its use as a reliable option for routine clinical testing.

"Energy-resolved attenuation behaviour on dual-source photon-counting CT: Implications for quantitative assessment of femoral bone marrow in multiple myeloma"

Source

Anke Heidemeier, Franzisca Scheiner, Henner Huflage, Simon Lennartz, Andreas Steven Kunz, Philipp Feldle, Thorsten Alexander Bley, Jan-Peter Grunz, Energy-resolved attenuation behaviour on dual-source photon-counting CT: Implications for quantitative assessment of femoral bone marrow in multiple myeloma, European Journal of Radiology, 2026, 113001, ISSN 0720-048X, https://doi.org/10.1016/j.ejrad.2026.113001. June 10, 2026. 

Overview

Researchers evaluated how different photon-counting CT (PCD-CT) energy settings affect bone marrow measurements used to assess multiple myeloma. The study found that bone marrow attenuation varies significantly with image energy, indicating that quantitative CT analyses should account for surrounding tissue characteristics rather than relying on fixed attenuation thresholds.

"Verification and optimization of the VTE risk stratification system for multiple myeloma"

Source

Liu, Y., Li, Q., Guo, H. et al. Verification and optimization of the VTE risk stratification system for multiple myeloma. J Thromb Thrombolysis (2026). https://doi.org/10.1007/s11239-026-03339-8 June 10, 2026. 

Overview

Researchers developed and validated an optimized risk model to better predict venous thromboembolism (VTE) in patients with newly diagnosed multiple myeloma. By incorporating female sex, bed rest at diagnosis, elevated platelet count, and thromboprophylaxis status, the model more accurately identified patients at risk for blood clots than existing scoring systems, although larger prospective studies are needed to confirm its usefulness.

"Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype"

Source

Alana L. Keller, Kady A. Dennis, Denis J. Ohlstrom, Sarah E. Parzych, Zachary J. Walker, Amanda J. Novak, Catherine Pham-Danis, Tanisha N. Medha, Jeremy T. Rahkola, Meher P. Boorgula, M. Eric. Kohler, Daniel W. Sherbenou; Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype. Cancer Immunol Res 2026; https://doi.org/10.1158/2326-6066.CIR-25-1068  June 10, 2026. 

Overview

Researchers investigated why some multiple myeloma cells survive BCMA-directed CAR T-cell therapy and bispecific antibodies. The study found that resistant myeloma cells consistently increased CD45 and activated immune evasion pathways, suggesting that combining T-cell–redirecting therapies with immune checkpoint inhibitors may help overcome treatment resistance.
 

"Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis"

Source

Patel, K., Hasegawa, K., Sidana, S., Ting, J., Zoratti, M. J., Wennersbusch, D., … Hansen, D. K. (2026). Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis. Expert Review of Hematology. https://doi.org/10.1080/17474086.2026.2688385  June 10, 2026. 

Overview

Researchers conducted a systematic review and meta-analysis to identify the clinical and disease characteristics that most strongly influence outcomes with CAR T-cell and bispecific antibody therapies in relapsed or refractory multiple myeloma. The study identified several key prognostic factors—including high-risk cytogenetics, extramedullary disease, prior BCMA-targeted therapy, and triple-class refractory disease—that should be considered when comparing treatments and informing clinical and policy decisions.

"Scavenger receptor class B type I (SR-BI) as a potential therapeutic target in multiple myeloma"

Source

Kondo, Y., Yano, H., Fujiwara, Y. et al. Scavenger receptor class B type I (SR-BI) as a potential therapeutic target in multiple myeloma. Med Mol Morphol (2026). https://doi.org/10.1007/s00795-026-00466-2 June 10, 2026.  

Overview

Researchers investigated how abnormal cholesterol metabolism contributes to multiple myeloma progression by examining lipid accumulation in myeloma cells and patient samples. The study found that the cholesterol transporter SR-BI plays a key role in myeloma cell survival, suggesting that targeting cholesterol trafficking pathways could represent a promising new therapeutic strategy.

"Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC"

Source

Youssef, N., Hameed, M., Atrash, S., Paul, B., Khan, A. M., Shaikh, H., Strouse, C., Vegel, A., Chahine, Z., Mazloom, A., Faisal, M. S., Al-Juhaishi, T., Alkharabsheh, O., Zayad, A., Awadallah, C., Snyder, J., Mahmoudjafari, Z., Umair Mushtaq, M., Kort, J., ... Waheed, S. (2026). Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC. Current Oncology, 33(6), 355. https://doi.org/10.3390/curroncol33060355  June 11, 2026.  

Overview

Researchers evaluated real-world treatment sequencing after BCMA-directed therapies in relapsed or refractory multiple myeloma. The analysis found that BCMA CAR T-cell therapy produced the best outcomes after prior BCMA treatment, while waiting at least six months before another T-cell–redirecting therapy and switching to a non-BCMA target, such as talquetamab, improved responses in patients with treatment-resistant disease.
 

"Validation and Exploratory Refinement of the HFA-ICOS Score for Cardiovascular Risk in Proteasome Inhibitor-Treated Multiple Myeloma: Single-Center Retrospective Study"

Source

Pons-Fuster, E., Riquelme-Perez, A., Shumbar, V., González-Ponce, C. M., Fernandez-Avila, J. J., Ramón-Martínez, A., Moreno-Belmonte, M. J., Cabañas-Perianes, V., Pascual-Figal, D., Diaz-Carrasco, M. S., & Caro-Martínez, C. (2026). Validation and Exploratory Refinement of the HFA-ICOS Score for Cardiovascular Risk in Proteasome Inhibitor-Treated Multiple Myeloma: Single-Center Retrospective Study. Cancers, 18(12), 1924. https://doi.org/10.3390/cancers18121924  June 11, 2026. 

Overview

Researchers evaluated whether the Heart Failure Association–International Cardio-Oncology Society (HFA-ICOS) risk score accurately predicts cardiovascular complications in patients with multiple myeloma receiving proteasome inhibitors. The study found that incorporating early NT-proBNP testing, carfilzomib exposure, and age ≥65 years improved prediction of cardiovascular risk, although the refined model requires validation before routine clinical use.
 

"Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma"

Source

Eden Biltibo et al. Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma. Am Soc Clin Oncol Educ Book 46, e517460(2026). DOI:10.1200/EDBK-26-517460  June 11, 2026 

Overview

Researchers reviewed the side effects of bispecific antibodies used to treat multiple myeloma, focusing on their timing, severity, and management. The review highlights that while cytokine release syndrome (CRS) and neurologic toxicities are usually mild and occur early in treatment, infections remain the most significant long-term risk, emphasizing the importance of preventive measures and ongoing monitoring throughout therapy.
 

"Clinical evaluation of ex vivo expanded MUC1-specific peripheral blood T Cells for adoptive immunotherapy in relapsed/refractory multiple myeloma"

Source

Erin W. Meermeier, Dara S. Missan, Latha B. Pathangey, Caleb K. Stein, Gabrielle A. Reckard, Susie A. Darvish, Gregory J. Ahmann, Jill Adamski, Rafael Fonseca, Sandra J. Gendler, Michael P. Gustafson, P. Leif Bergsagel; Clinical evaluation of ex vivo expanded MUC1-specific peripheral blood T Cells for adoptive immunotherapy in relapsed/refractory multiple myeloma. Cancer Research Communications 2026; https://doi.org/10.1158/2767-9764.CRC-25-0713  June 11, 2026. 

Overview

Researchers evaluated the feasibility and safety of using patient-derived, MUC1-targeted T cells as an adoptive cell therapy for relapsed or refractory multiple myeloma. Although no objective responses were observed, the treatment was well tolerated, one patient achieved stable disease for two years, and the findings support further development of this personalized immunotherapy approach.
 

"A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study"

Source

Song Jin, Zhaohui Liao, Shuang Yan, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Fang Tang, Ziling Zhu, Depei Wu, Nishanthan Rajakumaraswamy, Yi Luo, Daijing Yuan, Hua Jiang, Zonghai Li, Chengcheng Fu; A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study. Blood 2026; blood.2025032112. doi: https://doi.org/10.1182/blood.2025032112  June 11, 2026. 

Overview

Researchers developed an allogeneic BCMA-targeted CAR T-cell therapy (CT0590) engineered to resist attack by the patient's immune system using NKG2A technology. In an early clinical trial, the treatment was well tolerated and produced durable responses, including long-lasting stringent complete responses in patients with relapsed or refractory multiple myeloma and primary plasma cell leukemia, supporting further clinical development of this off-the-shelf CAR T-cell approach.
 

"Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1"

Source

Vishwamitra D, Skerget S, Cortes-Selva D, Perova T, Lau O, Davis C, Boominathan R, Patel J, Berge KV den, Guo Y, Miao X, Stephenson T, Hodin C, Uhlar C, Pei L, Trancucci D, Zuppa AF, Chastain K, Banerjee A, Kobos R, Bahlis NJ, van de Donk NW, Verona RI. Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1. Haematologica; https://doi.org/10.3324/haematol.2026.300526 [Early view].  June 11, 2026.  

Overview

Researchers examined how the immune system and BCMA expression change over time in patients treated with teclistamab to better understand why some patients respond while others develop resistance or relapse. The study found that persistent T-cell dysfunction, increased regulatory T cells, and reduced BCMA expression were associated with treatment resistance and relapse, providing insights that could help optimize teclistamab combinations, sequencing, and earlier use.
 

"The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study"

Source

Kim M, Jang HC, Ahn J-S, Cho H, Lee J-J, Cho HJ, Kim DS, Jung J, Lee JH, Kim K, Byun JM, Yoon DH, Choi YS, Jo J-C, Yhim H-Y, Lee M-W, Lim S-N, Lee JH, Park S-S, Min C-K, Jung S-H. The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study. Haematologica; https://doi.org/10.3324/haematol.2026.300772 [Early view]. June 11, 2026. 

Overview

Researchers analyzed clinical outcomes and single-cell gene expression in patients with primary plasma cell leukemia (pPCL) to identify factors associated with survival and better understand the disease's biology. The study confirmed that poor performance status, elevated lactate dehydrogenase (LDH), and del(17p) predicted early mortality, while achieving a complete response was the strongest predictor of longer survival, and exploratory molecular findings suggested immune-related mechanisms that may contribute to the disease's aggressive behavior.
 

"Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma"

Source

Jerald D Noble, Barbara C Peixoto, Meghan A Menges, Julieta Abraham-Miranda, Constanza Savid-Frontera, William Sawyer, Vasu D Sorathia, Luis A. Cuadrado Delgado, Salvatore A Corallo, Julia Christine Llanos, Emily C Merritt, Gabriel De Avila, Omar Alexis Castaneda-Puglianini, Hien D Liu, Melissa Alsina, Taiga Nishihori, Kenneth H Shain, Ariosto S Siqueira Silva, Rachid C Baz, Brandon J Blue, Ariel F Grajales-Cruz, Doris K Hansen, John L Cleveland, Fabiana Perna, Conor C Lynch, Jennifer M Binning, Reginald M Atkins, Xiaofei Song, Frederick L. Locke, Ciara L Freeman; Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma. Blood 2026; blood.2025031843. doi: https://doi.org/10.1182/blood.2025031843  June 11, 2026. 

Overview

Researchers used single-cell RNA sequencing to identify features of idecabtagene vicleucel (ide-cel) CAR T-cell products associated with durable responses in relapsed or refractory multiple myeloma. The study found that strong NF-κB signaling and a central memory T-cell phenotype were linked to longer progression-free and overall survival, suggesting these characteristics may serve as biomarkers of CAR T-cell fitness and targets for improving future CAR T-cell therapies.
 

"Study of NSD2 using a dTAG system reveals its molecular mechanism and oncogenic implications in t(4;14) multiple myeloma"

Source

Yubao Wang, Sanxiong Liu, Hussein Ghamlouch, Dylan C. Gagler, Patrick Blaney, Behnam Nabet, Faith E. Davies, Gareth J. Morgan; Study of NSD2 using a dTAG system reveals its molecular mechanism and oncogenic implications in t(4;14) multiple myeloma. Blood 2026; 147 (24): 2916–2929. doi: https://doi.org/10.1182/blood.2025031663  June 11, 2026. 

Overview

Researchers investigated how the NSD2 gene, which is overactive in t(4;14) multiple myeloma, drives disease by altering gene regulation. The study found that NSD2 reshapes the epigenetic landscape to activate cancer-promoting genes and identified multiple oncogenic pathways controlled by NSD2, supporting its potential as a therapeutic target in this high-risk subtype of multiple myeloma.
 

"Cardiovascular Comorbidities and Advanced Chronic Kidney Disease in Hospitalized Patients with Multiple Myeloma: A Single-Center Retrospective Cohort Study"

Source

Bălăceanu, L. A., Tiron, A. T., Baboi, I. D., Iacobescu, C. G., Bălăceanu-Gurău, B., Gurău, C.-D., Grigorescu, I. V., & Dina, I. (2026). Cardiovascular Comorbidities and Advanced Chronic Kidney Disease in Hospitalized Patients with Multiple Myeloma: A Single-Center Retrospective Cohort Study. Diseases, 14(6), 214. https://doi.org/10.3390/diseases14060214  June 12, 2026. 

Overview

Researchers examined the relationship between advanced chronic kidney disease (CKD) and cardiovascular comorbidities in hospitalized patients with multiple myeloma. The study found that atrial fibrillation and myocardial ischemia were associated with advanced CKD in initial analyses, highlighting the frequent coexistence of kidney and cardiovascular disease in this population and the need for comprehensive clinical management.

"Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis"

Source

Xia, F., Lv, B., Li, X. et al. Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis. BMC Med (2026). https://doi.org/10.1186/s12916-026-04988-5  June 12, 2026. 

Overview

Researchers evaluated blood transfusion requirements in patients with relapsed or refractory multiple myeloma treated with CAR T-cell therapy to determine whether they predict clinical outcomes. The study found that while early transfusions reflected treatment-related inflammation and acute toxicity, the need for late transfusions, particularly red blood cell transfusions, was associated with poorer responses, shorter survival, and higher non-relapse mortality.

"Microchromosome maintenance protein 2 is essential in immune infiltration-correlated prognosis of multiple myeloma patients by regulating cell cycle"

Source

Maihemaiti, A., Tang, L., Zhou, H. et al. Microchromosome maintenance protein 2 is essential in immune infiltration-correlated prognosis of multiple myeloma patients by regulating cell cycle. Cell Oncol. (2026). https://doi.org/10.1007/s13402-026-01241-2  June 12, 2026.  

Overview

Researchers developed an immune-based prognostic model to predict outcomes in patients with newly diagnosed multiple myeloma and identify new therapeutic targets. The study identified MCM2 as a key driver of disease progression and found that inhibiting MCM2 slowed myeloma growth and enhanced the effectiveness of PD-1/PD-L1 immunotherapy, suggesting a promising combination treatment strategy.

"Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma"

Source

J. Richter, Y. Efebera, H. Yimer, et al., “Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma,” American Journal of Hematology (2026): 1–6, https://doi.org/10.1002/ajh.70408.  June 12, 2026. 

Overview

Researchers conducted an indirect treatment comparison to evaluate how belantamab mafodotin plus bortezomib and dexamethasone (BVd) compares with other approved regimens for patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. The analysis found that BVd was associated with longer progression-free survival and, in most comparisons, improved overall survival versus several standard treatments, supporting its role as an effective and accessible treatment option in later-line myeloma

"Genomic features do not account for differences in multiple myeloma risk by ancestry"

Source

Kylee H. Maclachlan, Marios Papadimitriou, Patrick Blaney, Linda B. Baughn, Tala Shekarkhand, Alexandra M. Poos, Bachisio Ziccheddu, Hongwei Tang, Huihuang Yan, Benjamin Diamond, Yanming Zhang, Robert Cimera, Ahmet Dogan, Dylan Gagler, Eileen Boyle, Malin Hultcrantz, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Carlyn Tan, Elizabeth E. Brown, Lara Winterkorn, Timothy Chu, Zoe Steinsnyder, Zalman Vaksman, Faith E. Davies, Neha Korde, Ola Landgren, Marc S. Raab, Alexander M. Lesokhin, Nicolas Robine, Niels Weinhold, Saad Z. Usmani, Francesco Maura, Gareth J. Morgan; Genomic features do not account for differences in multiple myeloma risk by ancestry. Blood Cancer Discov 2026; https://doi.org/10.1158/2643-3230.BCD-25-0259  June 12, 2026. 

Overview

Researchers investigated whether genetic differences contribute to racial disparities in multiple myeloma by analyzing whole-genome sequencing data from more than 1,200 patients. The study found no germline or tumor genomic differences that explain the higher incidence of myeloma in individuals with African ancestry and showed that, when patients have equal access to effective therapies, clinical outcomes are comparable across ancestry groups.

"Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma"

Source

Maximilian Merz, Tomas Jelinek, Thomas Pabst, Raphael Teipel, Anca-Maria Albici, Bastian von Tresckow, Marcel Teichert, Uta Margareta. Demel, Antonia Busse, Marie Christine. Wesener, Tobias A. W. Holderried, Friederike Schmitz, Friedrich-Linus Rößiger, Fabian Müller, Michele Hoffmann, Friedrich Stölzel, Natalia Tovar, Ben-Niklas Baermann, Martin Stork, Alexandra Jungova, Jiri Minarik, Jakub Radocha, Ivan Spicka, Ludek Pour, Polona Novak, Klara Slajpah, Karla Rener, Ulrich Keller, Stephan Bohl, David Fandrei, Patrick Born, Vladan Vucinic, Nicolaus Kröger, Irene Strassl, Natalie Schub, Roman Hájek, Matjaz Sever, Carlos Fernández de Larrea, Nico Gagelmann; Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. Blood Cancer Discov 2026; https://doi.org/10.1158/2643-3230.BCD-25-0461  June 12, 2026. 

Overview

Researchers evaluated how the sequence of CAR T-cell therapy and bispecific antibodies affects outcomes in patients with relapsed or refractory multiple myeloma. The study found that patients who received both therapies sequentially, particularly those who started with CAR T-cell therapy, tended to have the longest remissions, highlighting the importance of optimizing treatment sequencing and ensuring timely access to both immunotherapy approaches.

"Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study"

Source

Attaya Suvannasankha, Mengying Li, Omonefe Omofuma, Christian Hampp, Matthew Phelan, Alexander Breskin, Ping Shao, Tito Roccia, Nandita Mukherjee, Anju Shrestha, Daniel Lee, Jacob Glass, Glenn S. Kroog, Karen Rodriguez Lorenc; Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study. Clin Cancer Res 2026; https://doi.org/10.1158/1078-0432.CCR-25-4068  June 12, 2026. 

Overview

Researchers compared the risk of second primary malignancies (SPMs) in patients with multiple myeloma treated with CAR T-cell therapy versus other systemic anticancer therapies. The study found no significant difference in the overall risk of second cancers, although hematologic malignancies were reported more frequently after CAR T-cell therapy, a finding that may have been influenced by increased monitoring and warrants further investigation.

"Clinical implications and predictors of MRD resurgence in ASCT-eligible patients with NDMM: a real-world study in China"

Source

Li, X., Chen, M., Liu, J., Gu, J., Huang, B., Kuang, L., & Li, J. (2026). Clinical implications and predictors of MRD resurgence in ASCT-eligible patients with NDMM: a real-world study in China. Future Oncology, 1–11. https://doi.org/10.1080/14796694.2026.2681675 June 12, 2026.  

Overview

Researchers evaluated the clinical significance of minimal residual disease (MRD) resurgence in transplant-eligible patients with newly diagnosed multiple myeloma after achieving MRD negativity. The study found that patients with high-risk cytogenetics, delayed MRD negativity, and certain clinical features were more likely to lose MRD-negative status, and that early treatment modification after MRD resurgence was associated with longer progression-free survival.

"Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy"

Source

Jean-Roch Le Henaff, Loïc Le Guennec, Pauline Schiro, Kevin Bihan, Jacques Gasnault, Bruno Stankoff, Yassine Taoufik, Emmanuel Treiner, Daniele Bensoussan, Sebastien Lhomme, Anne-Sophie L'Honneur, Fabrice Bonneville, Natalia Shor, Valérie Pourcher, Béatrice Pignolet, Baptiste Lievin, Clément Javaux, Julien Le Guen, Eolia Brissot, Pierre-Antoine Limouzin, Clémence Richaud, Bruno Lioure, Thomas Wirth, Paul Petitgas, Simon Herbel, François Coustillères, Elena-Camelia Rusu, Laura Maerten, Aurore Perrot, Agnès Sommet, Damien Roos-Weil, Margaux Lafaurie, Nicolas Weiss, Guillaume Martin-Blondel; Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy. Blood Adv 2026; bloodadvances.2026020556. doi: https://doi.org/10.1182/bloodadvances.2026020556  June 12, 2026.  

Overview

Researchers investigated the risk of progressive multifocal leukoencephalopathy (PML) in patients with multiple myeloma treated with bispecific antibodies by analyzing national and international pharmacovigilance data. The study identified an increased reporting signal for this rare but often fatal brain infection, emphasizing the need to promptly evaluate new or worsening neurologic symptoms in patients receiving bispecific antibody therapy.

"Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis"

Source

Sabrine Nakaa, Leo Caillot, Akli Chermak, Helene Kemp, Stéphanie Harel, Michael Darmon, Elie Azoulay, Virginie Lemiale, Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis, Annals of Intensive Care, 2026, 100100, ISSN 2110-5820, https://doi.org/10.1016/j.aicoj.2026.100100. June 13, 2026. 

Overview

Researchers evaluated intensive care unit (ICU) outcomes in patients with multiple myeloma over a 16-year period to determine how advances in myeloma treatment have affected survival. The study found that ICU and long-term survival improved significantly in recent years, particularly among patients who had not received extensive prior treatment, supporting timely ICU admission for appropriate patients with multiple myeloma..

"Insulin Signaling-Inducible IFITM1 Promotes Multiple Myeloma Progression and Bortezomib Resistance"

Source

J.-Y. Lim, Y. Kim, S.-S. Park, J. Lee, and C.-K. Min, “Insulin Signalling-Inducible IFITM1 Promotes Multiple Myeloma Progression and Bortezomib Resistance,” Journal of Cellular and Molecular Medicine30, no. 11 (2026): e71183, https://doi.org/10.1111/jcmm.71183.  June 12, 2026.   

Overview

Researchers investigated how insulin signaling contributes to multiple myeloma progression and resistance to proteasome inhibitors. The study found that insulin and IGF-II promote myeloma cell growth and reduce sensitivity to bortezomib and carfilzomib through upregulation of IFITM1, identifying IFITM1 as a potential prognostic biomarker and therapeutic target.

"Elranatamab Population Pharmacokinetics and Exposure–Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma"

Source

Hibma, J.E., Irby, D., Liu, A. et al. Elranatamab Population Pharmacokinetics and Exposure–Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet (2026). https://doi.org/10.1007/s40262-026-01663-z  June 13, 2026.   

Overview

Researchers developed a population pharmacokinetic (PopPK) model to better understand how elranatamab is processed in patients with relapsed or refractory multiple myeloma and to optimize its dosing. The study found that patient characteristics had little effect on drug exposure, supported the approved fixed-dose regimen, and showed that treatment can generally be restarted without re-priming after interruptions of up to 12 weeks.

"MonumenTAL-3 Investigators. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma"

Source

Mina R, Beksac M, Rodríguez-Otero P, Chen W, Mateos MV, Li J, Moreau P, Cohen YC, Min CK, Jelinek T, Ye JC, Magen H, Rubinstein SM, Fu W, Hungria V, Cengiz Seval G, Farias JS, Radocha J, Maral S, Turgut M, Koh Y, O'Leary D, Schmidt Filho J, Thertulien R, An G, Huang SY, Grosicki S, Tyczyńska A, Banerjee R, Pianko MJ, Martínez-López J, Steckiewicz P, Maruyama D, Fukushima K, Oriol A, Lopez Pardo J, Goldschmidt H, Pawlyn C, Perrot A, Zamagni E, Dimopoulos MA, Rasche L, Tolbert J, Terry W, Courtoux C, Liu X, Vasey SY, Connors K, Festa M, Heuck C, Langlois A, O'Rourke L, Zhou J, Qin X, Lu J, Gong J, Vieyra D, Voorhees PM; MonumenTAL-3 Investigators. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. N Engl J Med. 2026 Jun 13. doi: 10.1056/NEJMoa2604657. 

Overview

Researchers evaluated whether adding talquetamab to daratumumab, with or without pomalidomide, improves outcomes for patients with relapsed or refractory multiple myeloma after at least one prior line of therapy. The phase 3 study found that both talquetamab-based regimens significantly improved progression-free survival, response rates, MRD-negative complete responses, and overall survival compared with standard daratumumab, pomalidomide, and dexamethasone (DPd), supporting these combinations as new treatment options in early relapse.

"Real-world evidence of immunotherapy sequencing in multiple myeloma: Durable responses with BCMA-targeting bispecific antibodies following prior GPRC5D-targeting therapy"

Source

Titouan Cazaubiel, Cyrille Touzeau, Laure Vincent, Karim Belhadj, Lionel Karlin, Salomon Manier, Aurore Perrot, Marie Christiane Vekemans, Perrine Moyer, Philippe Moreau, Mohamad Mohty, Judith Victor, Cyrille Hulin, Real-world evidence of immunotherapy sequencing in multiple myeloma: Durable responses with BCMA-targeting bispecific antibodies following prior GPRC5D-targeting therapy., Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.06.005. June 14, 2026. 

Overview

Researchers evaluated the effectiveness and safety of BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma who had previously been treated with GPRC5D-targeting bispecific antibodies. The study found that sequential treatment with a BCMA-targeting bispecific antibody produced meaningful responses with a manageable safety profile, supporting this sequencing strategy as a viable option after GPRC5D-directed therapy.

"Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma"

Source

Rosenberg, T., Kirkegaard, J., Gundesen, M. T., Ølholm, A. M., Dieperink, K. B., & Lund, T. (2026). Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma. Hematology Reports, 18(3), 41. https://doi.org/10.3390/hematolrep18030041  June 14, 2026. 

Overview

Researchers evaluated whether digital patient-reported outcomes (PROs) could safely replace routine pre-treatment telephone assessments for patients with multiple myeloma receiving home-based daratumumab. The study found that digital symptom reporting accurately identified patients who were ready for treatment and could eliminate nearly 80% of routine pre-treatment phone calls, suggesting a feasible approach to streamline care while maintaining patient safety.

"Cardiovascular Toxicity of Monoclonal Antibodies Approved for Multiple Myeloma: Evidence Based on FAERS Database"

Source

Liang, T., Li, J. & Xu, C. Cardiovascular Toxicity of Monoclonal Antibodies Approved for Multiple Myeloma: Evidence Based on FAERS Database. Ther Innov Regul Sci (2026). https://doi.org/10.1007/s43441-026-00967-3  June 14, 2026. 

Overview

Researchers analyzed a large pharmacovigilance database to evaluate the risk of cardiovascular toxicities associated with monoclonal antibodies used to treat multiple myeloma. The study found safety signals linking these therapies—particularly daratumumab, isatuximab, and elotuzumab—to heart failure, embolic and thrombotic events, hypertension, and arrhythmias, highlighting the importance of cardiovascular monitoring during treatment.

"SUCCESSOR-2 Trial Investigators. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial"

Source

Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoé E, Gálvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG; SUCCESSOR-2 Trial Investigators. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Lancet. 2026 Jun 14:S0140-6736(26)01088-3. doi: 10.1016/S0140-6736(26)01088-3. Epub ahead of print. 

Overview

Researchers evaluated whether adding mezigdomide to carfilzomib and dexamethasone improves outcomes for patients with relapsed multiple myeloma who are anti-CD38 antibody- and lenalidomide-refractory. The phase 3 trial found that the mezigdomide combination significantly prolonged progression-free survival compared with carfilzomib and dexamethasone alone, supporting it as a promising treatment option at first relapse despite higher rates of manageable side effects.

"Safety profile of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials"

Source

Filippatos, C., Ntanasis-Stathopoulos, I., Voulomenou, A., Malandrakis, P., Kastritis, E., Gavriatopoulou, M., Dimopoulos, M.-A. and Terpos, E. (2026), Safety profile of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials. Br J Haematol. https://doi.org/10.1111/bjh.70624  June 15, 2026. 

Overview

Researchers conducted a systematic review and meta-analysis to comprehensively evaluate the safety profile of CAR T-cell therapies in patients with relapsed or refractory multiple myeloma. The study found that while severe immune-related toxicities such as cytokine release syndrome and neurotoxicity were uncommon, high-grade blood-related toxicities and infections were frequent, and identified patient characteristics associated with increased toxicity risk to help guide monitoring and supportive care.

"Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma"

Source

J. McElwee, G. Elsey, R. Gonzalez, et al., “Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma,” American Journal of Hematology (2026): 1–6, https://doi.org/10.1002/ajh.70414.  June 15, 2026. 

Overview

Researchers compared dexamethasone with tocilizumab as the initial treatment for low-grade cytokine release syndrome (CRS) in patients receiving talquetamab for relapsed or refractory multiple myeloma. The study found that dexamethasone effectively resolved most cases of grade 1 CRS without compromising treatment responses, supporting it as a safe, accessible, and lower-cost first-line option for managing low-grade CRS.

"Non-ICANS neurotoxicity after BCMA-directed CAR-T therapy: Clinical spectrum, outcomes, and a framework for neurology–oncology co-management"

Source

Werner, J.-M., Gödel, P., Galldiks, N., Krone, C., Schroeter, M., Holtick, U., Flümann, R., Wunderlich, G., Hallek, M., Fink, G.R., Scheid, C., Onur, O.A. and Richardson, T. (2026), Non-ICANS neurotoxicity after BCMA-directed CAR-T therapy: Clinical spectrum, outcomes, and a framework for neurology–oncology co-management. HemaSphere, 10: e70404. https://doi.org/10.1002/hem3.70404  June 15, 2026.  

Overview

Researchers compared dexamethasone with tocilizumab as the initial treatment for low-grade cytokine release syndrome (CRS) in patients receiving talquetamab for relapsed or refractory multiple myeloma. The study found that dexamethasone effectively resolved most cases of grade 1 CRS without compromising treatment responses, supporting it as a safe, accessible, and lower-cost first-line option for managing low-grade CRS.

"Psychometric properties of patient-reported outcome measures for health-related quality of life in multiple myeloma: a systematic review based on COSMIN guidelines"

Source

Xie, L., Feng, Q., Wang, J. et al. Psychometric properties of patient-reported outcome measures for health-related quality of life in multiple myeloma: a systematic review based on COSMIN guidelines. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-16341-3  June 15, 2026. .  

Overview

Researchers conducted a systematic review to identify and evaluate patient-reported outcome measures (PROMs) used to assess quality of life, symptoms, and disease burden in patients with multiple myeloma. The study found that the EORTC QLQ-MY20 and MyPOS have the strongest supporting evidence for measuring health-related quality of life, while highlighting the need for further validation to improve their use in clinical trials and routine care.

"Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study"

Source

Di Cecca, M., V., Bongarzoni, M., Garzia, F., Fazio, V., Tomarchio, G., Barilà, C., Liberatore, A., Rago, B., Rossini, S., Rocco, F., Pisani, L., De Padua, L., Fiori, M. T., Tafuri, B., Anaclerico, L., Cardarelli, E., Scomazzon, F., Fioritoni, T., Caravita Di Torritto, A. M., Quinto, S., Palmieri, M., Lamanda, A., Tamburini, A., Piciocchi, M. T., Petrucci, L., Rigacci, O., Annibali, Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study, Advances in Hematology, 2026, 5597825, 7 pages, 2026. https://doi.org/10.1155/ah/5597825  June 15, 2026. 

Overview

Researchers evaluated the impact of COVID-19 vaccination and antiviral therapy on outcomes in patients with multiple myeloma receiving active treatment. The study found that receiving three or more vaccine doses, particularly when combined with antiviral treatment, reduced COVID-19 severity, hospitalization, and recovery time, highlighting the importance of these strategies in protecting this vulnerable population.

"Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma"

Source

De Coster, M., L. Hyka, S. De Cock, et al. 2026. “Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma.” Journal of Extracellular Vesicles15, no. 6: e70325. https://doi.org/10.1002/jev2.70325  June 15, 2026 

Overview

Researchers investigated whether engineered extracellular vesicles (EVs) targeting the CS1 protein could improve delivery of therapeutics to multiple myeloma cells in the bone marrow. While the engineered EVs enhanced uptake by myeloma cells in laboratory studies, they showed only limited improvement in bone marrow targeting in animal models, indicating that further optimization is needed before this approach can be used for targeted drug delivery.

"Response kinetics as a dynamic prognostic marker in patients with multiple myeloma"

Source

Cho, H.J., Lee, MW., Lee, J.H. et al. Response kinetics as a dynamic prognostic marker in patients with multiple myeloma. Leukemia (2026). https://doi.org/10.1038/s41375-026-03007-z  June 15, 2026. 

Overview

Researchers evaluated whether the timing of response to therapy (response kinetics) predicts outcomes in patients with relapsed or refractory multiple myeloma treated with carfilzomib- or ixazomib-based regimens. The study found that patients who achieved responses more gradually had longer progression-free and overall survival than rapid responders, suggesting that response kinetics may serve as a valuable prognostic marker beyond traditional risk factors.

"A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study"

Source

Schinke, C., Touzeau, C., Oriol, A., Mateos, M. V., Stevens, D., Rasche, L., … Chari, A. (2026). A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study. Future Oncology, 1–18. https://doi.org/10.1080/14796694.2026.2669331  June 16, 2026. 

Overview

This summary describes a study evaluating the health-related quality of life of patients with relapsed or refractory multiple myeloma treated with talquetamab. It found that although patients experienced a temporary decline in quality of life during the first few treatment cycles, most reported sustained improvements in physical functioning, symptoms, and overall well-being with continued treatment, supporting the long-term benefits of talquetamab beyond its clinical effectiveness.

"Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial"

Source

Hall A, Croft J, Walker K, Boyd K, Roberts S, Holroyd A, et al. Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial. Br J Haematol. 2026;00:1–12. https://doi.org/10.1111/bjh.70611  June 16, 2026 

Overview

Researchers evaluated whether adding cyclophosphamide to pomalidomide and dexamethasone improves outcomes for patients with relapsed or refractory multiple myeloma and examined how the combination affects the immune system. Although the study closed early and did not show a statistically significant improvement in progression-free survival, the three-drug combination produced higher response rates and favorable changes in T-cell populations, supporting its potential as an accessible treatment option.

"Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity"

Source

Corradini, S., Maksimos, M., Azab, F. et al. Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity. Leukemia (2026). https://doi.org/10.1038/s41375-026-03004-2  June 16, 2026. 

Overview

Researchers evaluated CBPD-409, a PROTAC degrader that eliminates the transcriptional regulators CBP and p300, as a potential treatment for multiple myeloma. The preclinical study found that CBPD-409 suppressed key myeloma growth pathways, induced cancer cell death, and reduced tumor growth in laboratory and animal models, supporting further clinical development of this targeted therapy.

"Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy"

Source

Sofie-Katrin Kadel, Lukas Scheller, Alexander M. Leipold, Tobias Krammer, Tamás Raskó, Miriam Alb, Philipp Weis, Maria Leberzammer, Friederike Schmitt, Clara Stetter, Yoko Tamamushi, Alicia Köck, Philipp Köberle, Martin Reich, Thomas Musacchio, Kathrin Doppler, Claudia Sommer, Nadine Cebulla, Rhonda McFleder, Chi Wang Ip, Jens Volkmann, Matthias Kallius, Sebastian E. Serfling, Philipp E. Hartrampf, Andreas K. Buck, Amit Pande, Dennis Löffler, Michael Gernert, Johannes Duell, Max S. Topp, Julia Mersi, Johannes Waldschmidt, Hermann Einsele, Michael Hudecek, Antoine-Emmanuel Saliba, Leo Rasche, K. Martin Kortüm; Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy. Blood Cancer Discov 2026; https://doi.org/10.1158/2643-3230.BCD-25-0278  June 16, 2026. 

Overview

Researchers investigated the immune mechanisms underlying a fatal case of parkinsonism that developed after treatment with ciltacabtagene autoleucel (cilta-cel). By analyzing blood and cerebrospinal fluid over six months, the study identified a two-stage immune process involving CAR T cells, inflammation, and disruption of the blood–brain barrier that may help explain this rare but serious neurological complication.

"Metabolic heterogeneity and niche rewiring in bone marrow plasma cells from patients with MGUS, solitary bone plasmacytoma and multiple myeloma"

Source

Zhang, G., Sun, N., Chawla, Y. et al. Metabolic heterogeneity and niche rewiring in bone marrow plasma cells from patients with MGUS, solitary bone plasmacytoma and multiple myeloma. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01525-8 June 16, 2026. 

Overview

Researchers used spatial metabolomics to compare metabolic changes in multiple myeloma (MM) with earlier plasma cell disorders such as MGUS and solitary bone plasmacytoma. The study identified distinct metabolic patterns within myeloma-rich areas of the bone marrow that were not detectable in blood alone, suggesting that spatial metabolomic profiling could improve risk stratification and provide new insights into myeloma progression.

"Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care"

Source

Sugi T, Kushi R, Hanai H, Nakano H, Imai Y, Inoue M, Ishii-Nozawa R, Hagihara M. Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care. J Oncol Pharm Pract. 2026 Jun 16:10781552261458307. doi: 10.1177/10781552261458307. Epub ahead of print. 

Overview

Researchers evaluated the risk factors for pomalidomide-induced skin rash in patients with multiple myeloma. The study found that patients with a history of lenalidomide-related skin rash or no recent proteasome inhibitor treatment were more likely to develop skin rash with pomalidomide, highlighting the importance of early monitoring and supportive care to help prevent treatment interruptions.

"Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis"

Source

Harzer, M., Gross-Fengels, N., Melzer, F. et al. Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis. Ann Hematol 105, 300 (2026). https://doi.org/10.1007/s00277-026-07118-6  June 16, 2026. 

Overview

Researchers analyzed real-world treatment outcomes in patients with extramedullary multiple myeloma (EMD), a rare and aggressive form of the disease that spreads outside the bone marrow. The study found that patients with EMD—particularly those with central nervous system, lung, or retroperitoneal involvement—had poor outcomes despite modern therapies, highlighting the urgent need for prospective clinical trials and standardized treatment strategies.

"The Current Role of Physiotherapy in Systemic Light-Chain (AL) Amyloidosis and Multiple Myeloma"

Source

Ríos-Sánchez, A., Riazzo-Benítez, M. A., & Ríos-Tamayo, R. (2026). The Current Role of Physiotherapy in Systemic Light-Chain (AL) Amyloidosis and Multiple Myeloma. Life, 16(6), 1018. https://doi.org/10.3390/life16061018  June 16, 2026. 

Overview

This review examines the role of physiotherapy, particularly exercise-based rehabilitation, in patients with systemic light-chain (AL) amyloidosis, while comparing the available evidence with the better-studied field of multiple myeloma. It highlights current evidence, identifies gaps in supportive care, and outlines opportunities to better integrate personalized physiotherapy into the multidisciplinary management of both diseases to improve quality of life and patient outcomes.

"Double vs. single autologous stem cell transplantation in patients with multiple myeloma and high‑risk factors: A systematic review and meta‑analysis"

Source

Qin, S., Liu, Y., Zhang, P., Zhou, Q., Xu, X., Liu, D. ... Chen, H. (2026). Double vs. single autologous stem cell transplantation in patients with multiple myeloma and high‑risk factors: A systematic review and meta‑analysis. Oncology Letters, 32, 349. https://doi.org/10.3892/ol.2026.15704  June 16, 2026.  

Overview

Researchers compared single versus double autologous stem cell transplantation (ASCT) after high-dose therapy in patients with multiple myeloma, with a focus on those with high-risk disease. This meta-analysis found that while double ASCT did not significantly outperform single ASCT followed by consolidation therapy, it produced deeper treatment responses overall and improved progression-free and overall survival in patients with high-risk myeloma, supporting its use as a treatment option for this subgroup.

"Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival"

Source

Gurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, Temitope Oloyede, Muhammad Bilal Abid, Sairah Ahmed, Mahmoud Aljurf, Rahul Banerjee, Asad Bashey, Amer M. Beitinjaneh, Natalie S. Callander, Paul Castillo, Bhagirathbhai Dholaria, Scott R. Goldsmith, Shahrukh Hashmi, Mohamed A. Kharfan-Dabaja, Hongtao Liu, Hira Mian, Taiga Nishihori, Kai Rejeski, Ayman Saad, Michael J. Slade, Cameron J. Turtle, Dan T. Vogl, Kirsten M. Williams, Baldeep Wirk, Marcelo C. Pasquini, Amy Moskop, Othman Salim Akhtar, Doris K. Hansen, Murali Janakiram, Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival, Transplantation and Cellular Therapy, 2026, ISSN 2666-6367, https://doi.org/10.1016/j.jtct.2026.06.021. June 16, 2026. 

Overview

Researchers evaluated the frequency and clinical impact of prolonged cytopenias after treatment with idecabtagene vicleucel (ide-cel) in patients with relapsed or refractory multiple myeloma. The study found that persistent low blood cell counts 30 days after CAR T-cell therapy were associated with shorter progression-free and overall survival, while the rarer cytopenias persisting to 100 days were linked to worse overall survival, highlighting the importance of monitoring and managing prolonged hematologic toxicity.

"Practical Management of Bispecific Antibodies in Multiple Myeloma"

Source

Carlyn Rose Tan et al. Practical Management of Bispecific Antibodies in Multiple Myeloma. JCO Oncol Pract 0, OP-26-00159 DOI:10.1200/OP-26-00159 June 17, 2026.  

Overview

Researchers reviewed the practical implementation of bispecific antibodies (BsAbs) for treating relapsed or refractory multiple myeloma in routine clinical practice. The review outlines strategies for patient selection, toxicity management, infection prevention, and outpatient care to help safely expand access to these therapies as they move into earlier lines of treatment.

"From Germline Susceptibility to Therapeutic Vulnerability: DNA Damage Response Gene Mutations Driving Multiple Myeloma Evolution and Precision Therapy, Human Mutation"

Source

Shen, Qian, Wang, Ying, Cai, Liuhuan, Qian, Juan, From Germline Susceptibility to Therapeutic Vulnerability: DNA Damage Response Gene Mutations Driving Multiple Myeloma Evolution and Precision Therapy, Human Mutation, 2026, 7757115, 8 pages, 2026. https://doi.org/10.1155/humu/7757115 June 17, 2026 

Overview

Researchers reviewed the role of inherited DNA damage response (DDR) gene mutations, such as BRCA1/2, ATM, and CHEK2, in the development and progression of multiple myeloma. The review highlights how these genetic alterations may influence disease risk, treatment response, and resistance, while exploring emerging precision medicine approaches, including PARP inhibitor–based therapies, for patients with DDR-related disease.

"High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas"

Source

Stork, M., Ondrouskova, E., Mayerova, J., Mareckova, A., Porc, J.P., Reigl, T., Mensikova, K., Sendlerova, N., Boichuk, I., Cieslar, J., Bilcikova, M., Adam, Z., Krejci, M., Sandecka, V., Knechtova, Z., Jelinkova, Z., Krticka, M., Nekuda, V., Rohan, T., Hrabcakova, V., Janska Vojtkova, L., Borsky, M., Radova, L., Jarosova, M., Pour, L. and Kotaskova, J. (2026), High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas. HemaSphere, 10: e70395. https://doi.org/10.1002/hem3.70395 June 17, 2026. 

Overview

Researchers reviewed the role of inherited DNA damage response (DDR) gene mutations, such as BRCA1/2, ATM, and CHEK2, in the development and progression of multiple myeloma. The review highlights how these genetic alterations may influence disease risk, treatment response, and resistance, while exploring emerging precision medicine approaches, including PARP inhibitor–based therapies, for patients with DDR-related disease.

"CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma"

Source

Ferment, B., Ouedrani, A., Talbot, A., Mouri, N., Zarnitzky, P., Stammler, R., Vaugeois, T., Diep, A., Harel, S., Royer, B., Theves, F., Forgeard, N., Allain, V., Caillat-Zucman, S. and Arnulf, B. (2026), CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma. HemaSphere, 10: e70391. https://doi.org/10.1002/hem3.70391  June 17, 2026. 

Overview

Researchers evaluated whether immune biomarkers, particularly CAR T-cell expansion after infusion, could predict outcomes in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel (ide-cel). The study found that greater CAR T-cell expansion was strongly associated with longer progression-free survival and deeper responses, suggesting that early monitoring of CAR T-cell kinetics may help identify patients at higher risk of treatment failure.

"Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma"

Source

El-Garf, S., Hammad, R., Kandeel, E. et al. Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma. J Egypt Natl Canc Inst 38, 35 (2026). https://doi.org/10.1186/s43046-026-00379-2  June 17, 2026. 

Overview

Researchers evaluated PD-1 and PD-L1 expression in the bone marrow microenvironment of patients with newly diagnosed multiple myeloma to better understand their role in immune dysfunction. The study found that PD-1/PD-L1 expression was associated with certain immune features, particularly in patients with advanced disease, but was not associated with treatment response, suggesting that this pathway alone does not predict clinical outcomes.

"Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma."

Source

Kraft, T.E., Marrer-Berger, E., Belli, S., Haegel, H., Schneider, A., Giusti, A.M., Bscheider, M., Jacob, W., Weisser, M., Blanco, L., Frances, N., Rossmann, E., Steiner, G., Azpiroz, A.Z., Paiva, B., Martinet, L. and Fauti, T. (2026), Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.70366  June 17, 2026. 

Overview

Researchers evaluated PD-1 and PD-L1 expression in the bone marrow microenvironment of patients with newly diagnosed multiple myeloma to better understand their role in immune dysfunction. The study found that PD-1/PD-L1 expression was associated with certain immune features, particularly in patients with advanced disease, but was not associated with treatment response, suggesting that this pathway alone does not predict clinical outcomes.

"Identification of Neutrophil Extracellular Traps-Related Biomarkers in Multiple Myeloma Using Machine Learning and Experimental Validation"

Source

Wu H, Zhu Y, Wang B, Yang W. Identification of Neutrophil Extracellular Traps-Related Biomarkers in Multiple Myeloma Using Machine Learning and Experimental Validation. Curr Med Chem. 2026 Jun 17. doi: 10.2174/0109298673438668260604035517. 

Overview

Researchers used **machine learning** and **experimental validation** to identify **neutrophil extracellular trap (NET)-related biomarkers** associated with **multiple myeloma**. The study identified **KIT, HGF, and F2RL1** as potential biomarkers linked to the immune microenvironment and disease biology, suggesting they could serve as future diagnostic markers or therapeutic targets.
 

"Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept"

Source

Fleischer, A., Roll, M., Panther, F. et al. Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept. Support Care Cancer 34, 668 (2026). https://doi.org/10.1007/s00520-026-10863-z June 17, 2026. 

Overview

Researchers evaluated the impact of talquetamab-related taste changes (dysgeusia) on eating habits and quality of life in patients with multiple myeloma and explored strategies to help manage these side effects. The study identified personalized dietary adaptations and developed an exploratory supportive care workflow and digital companion concept to guide nutrition management, although both require validation before routine clinical use.
 

"The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)"

Source

H. Ludwig, E. Terpos, F. Gay, et al., “The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN),” American Journal of Hematology (2026): 1–18, https://doi.org/10.1002/ajh.70397.  June 18, 2026. 

Overview

Researchers conducted a systematic review and meta-analysis to compare the effectiveness of maintenance therapies for patients with multiple myeloma after initial treatment. The analysis found that lenalidomide, proteasome inhibitors, and CD38-targeted therapies all prolonged progression-free survival, with daratumumab plus lenalidomide providing the greatest benefit, while lenalidomide showed the strongest evidence for improving overall survival in transplant-eligible patients.
 

"Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review"

Source

Benda, M., Reimann, P., Willenbacher, W. et al. Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review. Ann Hematol (2026). https://doi.org/10.1007/s00277-026-07140-8  June 18, 2026. 

Overview

Researchers conducted a systematic review of infections in patients with relapsed or refractory multiple myeloma treated with CAR T-cell therapies and bispecific antibodies (BsAbs). The review found that infections are common—particularly with BCMA-targeted therapies—and highlighted the importance of preventive strategies such as antiviral and Pneumocystis jirovecii pneumonia prophylaxis, immunoglobulin replacement, and extended dosing intervals to reduce infection risk while maintaining treatment effectiveness.
 

"Prognostic Value of Next-Generation Flow Cytometry Versus Dual-Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma"

Source

R. Zhang, W. Zhu, L. Cheng, et al., “Prognostic Value of Next-Generation Flow Cytometry Versus Dual-Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma,” Cancer Medicine15, no. 6 (2026): e72023, https://doi.org/10.1002/cam4.72023.  June 18, 2026 

Overview

Researchers compared next-generation flow cytometry (NGF) and dual-tracer PET/CT imaging for measuring minimal residual disease (MRD) in patients with newly diagnosed multiple myeloma. The study found that NGF was the strongest predictor of progression-free and overall survival, while PET/CT provided complementary value by detecting extramedullary disease that bone marrow testing could miss, supporting a combined, risk-adapted approach to MRD assessment.
 

"Prognostic impact of Dmax on baseline FDG-PET/CT in newly diagnosed multiple myeloma"

Source

Raffy L, Etchegaray C, Hindie E, Saut O, Hulin C, Schmitt A, Mesguich C. Prognostic impact of Dmax on baseline FDG-PET/CT in newly diagnosed multiple myeloma. Haematologica; https://doi.org/10.3324/haematol.2025.300090 [Early view].  June 18, 2026. 

Overview

Researchers evaluated whether FDG-PET/CT–derived imaging biomarkers could improve risk prediction in patients with newly diagnosed multiple myeloma. The study found that greater metabolic tumor burden and wider disease dissemination on PET/CT were independently associated with shorter progression-free and overall survival, suggesting these imaging measures could enhance baseline risk stratification and help guide treatment decisions.

 

"Calpain-2 inhibition alleviates hypercalcemia-driven multiple myeloma progression"

Source

Zeyuan Wang, Chaoying Yang, Yanpeng Wang, Zhiming Guo, Ruibo Jin, Ling Xiao, Jing Liu, Hui Zhou, Xiaojuan Xiao, Xu Han, Calpain-2 inhibition alleviates hypercalcemia-driven multiple myeloma progression, Biochemical Pharmacology, 2026, 118174, ISSN 0006-2952, https://doi.org/10.1016/j.bcp.2026.118174. June 18, 2026. . 

Overview

Researchers investigated whether hypercalcemia directly promotes multiple myeloma progression and examined the role of the calcium-regulated protein calpain-2 (CAPN2). The study found that elevated calcium levels stimulated myeloma cell growth through CAPN2, and that inhibiting CAPN2 reduced tumor growth and enhanced the activity of bortezomib and doxorubicin, identifying CAPN2 as a potential therapeutic target.

 

"Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival"

Source

Puertas B, Padilla I, Alejo E, Serra-Toral F, García-Mateo A, López-López R, et al. Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival. Br J Haematol. 2026;00:1–11. https://doi.org/10.1111/bjh.70606  June 18, 2026.  

Overview

Researchers evaluated whether measurable residual disease (MRD) detected in autologous stem cell collection (apheresis) products could predict outcomes in patients with multiple myeloma undergoing autologous stem cell transplantation. The study found that detectable MRD in the apheresis product was associated with lower rates of deep response, a higher risk of early relapse, and shorter progression-free survival, suggesting it may serve as an early biomarker of suboptimal treatment response.

 

"Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis"

Source

Zhang, L., Bangolo, A., Amoozgar, B., Gill, S., Zhao, J., Bhullar, G. S., Singareddy, S., Singh, S., Ortiz, H., Muench, A., Peake, S., Azam, K., Noe, W., Ghanem, J., De Graaf, E., Sookoo, A., Reddy, M. N. R. K., Boban, S., Sakil, S., ... Biran, N. (2026). Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis. Cancers, 18(12), 1996. https://doi.org/10.3390/cancers18121996  June 18, 2026. 

Overview

Researchers evaluated the safety and effectiveness of combining immune checkpoint inhibitors with radiation therapy in patients with heavily pretreated extramedullary multiple myeloma. The study found that the combination produced responses in nearly half of patients and was generally well tolerated, although most responses were not durable, supporting further prospective studies to identify patients most likely to benefit. 

 

"Breaking the Balance: Baseline Oxidative Stress and DNA Repair Capacity in Multiple Myeloma Therapy"

Source

Malamos, P., Deligianni, E., Voutetakis, K., Koutoulogenis, K., Papadodima, O., Terpos, E., & Souliotis, V. L. (2026). Breaking the Balance: Baseline Oxidative Stress and DNA Repair Capacity in Multiple Myeloma Therapy. Cancers, 18(12), 1995. https://doi.org/10.3390/cancers18121995  June 18, 2026. 

Overview

Researchers investigated how oxidative stress and DNA damage response (DDR) pathways are associated with response to melphalan-based therapy in patients with multiple myeloma. The study found that patients who did not respond to treatment had lower baseline DNA damage, greater DNA repair capacity, and reduced apoptosis, suggesting these biological features may help explain treatment resistance and could serve as future biomarkers after prospective validation.

 

"Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing"

Source

Buenache, N., Lasa, M., Arroyo, A., González, C., Haertle, L., Ruiz-Heredia, Y., Ayala, R., Alonso, R., Martín-Muñoz, A., Rosa-Rosa, J.M., González, V., Calasanz, M.J., Rodríguez-Otero, P., Rosiñol, L., De Arriba, F., Ocio, E.M., Oriol, A., González, Y., Sureda, A., Lakhwani, S., Clavero, M.E., Ibáñez, A., Gómez, C., Orfao, A., Mateos, M.-V., Lahuerta, J.J., Cedena, M.T., Bladé, J., San Miguel, J., Puig, N., Paiva, B. and Martínez-López, J. (2026), Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing. HemaSphere, 10: e70405. https://doi.org/10.1002/hem3.70405 June 18, 2026 

Overview

Researchers evaluated a highly sensitive blood-based circulating tumor DNA (ctDNA) test to monitor measurable residual disease in patients with multiple myeloma. The study found that ctDNA detection in peripheral blood was strongly associated with an increased risk of relapse and disease progression, suggesting this minimally invasive approach could complement bone marrow MRD testing and enable more frequent disease monitoring.

 

"Structural and functional characterization of Acyl-CoA Synthetase Long-Chain Family Member 3 (ACSL3) and its targeted inhibition by gramicidin in multiple myeloma"

Source

Yanhua Yue, Wenjing Du, Yingjie Miao, Fei Wang, Luo Lu, Yan Lin, Yang Cao, Yuqing Qi, Kefeng Li, Yan Liu, Weiying Gu, Structural and functional characterization of Acyl-CoA Synthetase Long-Chain Family Member 3 (ACSL3) and its targeted inhibition by gramicidin in multiple myeloma, International Journal of Biological Macromolecules, 2026, 153126, ISSN 0141-8130, https://doi.org/10.1016/j.ijbiomac.2026.153126. June 19, 2026. 

Overview

Researchers investigated how altered fatty acid metabolism contributes to multiple myeloma progression and relapse by identifying key metabolic drivers. The study identified ACSL3 as a potential therapeutic target and found that inhibiting it with gramicidin suppressed myeloma growth and improved prediction of disease recurrence, supporting further investigation of ACSL3-targeted therapies.
 

"Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients"

Source

Fiori, E., Bertschinger, M., Bacher, U., Hoffmann, M., Nilius, H., Seipel, K., & Pabst, T. (2026). Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients. Biomedicines, 14(6), 1392. https://doi.org/10.3390/biomedicines14061392  June 19, 2026.  

Overview

Researchers evaluated whether PPM1D mutations could predict outcomes in patients with relapsed or refractory multiple myeloma treated with bispecific antibodies. The study found that patients with PPM1D mutations experienced shorter progression-free survival, poorer short-term overall survival, and less durable responses, suggesting these mutations may serve as a potential biomarker for identifying patients at higher risk of poor outcomes, pending validation in larger prospective studies.

 

"Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients"

Source

Zhang, H., Wang, Y., Wang, X. et al. Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients. J Transl Med (2026). https://doi.org/10.1186/s12967-026-08430-5  June 19, 2026 

Overview

Researchers investigated whether pomalidomide could enhance the immune activity of dendritic cell-derived exosomes from patients with multiple myeloma. The study found that pomalidomide increased the immune-stimulating properties of these exosomes, leading to stronger CD8+ T-cell activation and greater myeloma cell killing, suggesting a potential strategy for developing exosome-based cancer vaccines for multiple myeloma.

 

"Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis"

Source

Spataro, F., Desantis, V., Dicuonzo, G. et al. Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis. Exp Hematol Oncol 15, 56 (2026). https://doi.org/10.1186/s40164-026-00798-w  June 20, 2026. 

Overview

Researchers evaluated the real-world risk of severe infections in patients with relapsed or refractory multiple myeloma receiving bispecific antibodies or CAR T-cell therapy. The analysis found that approximately one in four patients experienced a severe infection, with lower infection rates observed among CAR T-cell recipients than bispecific antibody recipients, highlighting the importance of considering infection risk when selecting T-cell–redirecting therapies.

 

"MRD in multiple myeloma: Moving from 'minimal' to 'measurable'"

Source

Raffaella Cassano Cassano, Rahul Banerjee, Aimaz Afrough, Andrew J. Portuguese, Richa Thakur, Kara Cicero, Mary Kwok, Laahn Foster, Gabriele Buda, Silviya Meletath, Sara Galimberti, Gaetano Serviddio, Madhav V. Dhodapkar, Danai Dima, MRD in multiple myeloma: Moving from “minimal” to “measurable”, Blood Reviews, 2026, 101413, ISSN 0268-960X, https://doi.org/10.1016/j.blre.2026.101413. June 20, 2026. 

Overview

Researchers reviewed the evolving role of measurable residual disease (MRD) testing in multiple myeloma, including advances in detection methods, clinically relevant thresholds, and its impact on patient care. The review highlights MRD negativity as a powerful predictor of outcomes and an emerging treatment endpoint, while arguing that the term "measurable residual disease" more accurately reflects its quantitative and clinical significance than the traditional term "minimal residual disease."

 

"Quantitative assessment of tumor burden in multiple myeloma using MY-RADS from whole-body MRI: comparison with established prognostic biomarkers"

Source

Xiong, X., Yan, Z., Wang, J. et al. Quantitative assessment of tumor burden in multiple myeloma using MY-RADS from whole-body MRI: comparison with established prognostic biomarkers. Cancer Imaging (2026). https://doi.org/10.1186/s40644-026-01076-y  June 20, 2026. 

Overview

Researchers evaluated whether whole-body MRI using the MY-RADS scoring system could accurately assess tumor burden in newly diagnosed multiple myeloma. The study found that MY-RADS measurements correlated with established prognostic markers and bone marrow plasma cell infiltration, suggesting whole-body MRI may serve as a useful surrogate biomarker when standard prognostic tests are not readily available.

"Bone Marrow Homing and GPRC5D-Targeting Engineered Cell Membrane-Camouflaged Hypoxia-Responsive Nanoparticles for Multiple Myeloma Therapy"

Source

B. Chu, S. Li, X. Wei, et al. “Bone Marrow Homing and GPRC5D-Targeting Engineered Cell Membrane-Camouflaged Hypoxia-Responsive Nanoparticles for Multiple Myeloma Therapy.” Advanced Functional Materials (2026): e32144. https://doi.org/10.1002/adfm.202532144 June 21, 2026. 

Overview

Researchers developed a targeted nanoparticle system designed to improve delivery of bortezomib to multiple myeloma cells in the bone marrow. In preclinical models, the engineered nanoparticles selectively accumulated in the bone marrow, released the drug within the hypoxic tumor environment, and more effectively suppressed myeloma growth than conventional drug delivery, highlighting a promising strategy for targeted therapy.
 

"Transcription factor, E4BP4, inhibits autophagy and apoptosis in multiple myeloma and promotes the HDAC3-mediated suppression of the Beclin1 promoter to reduce dexamethasone sensitivity"

Source

Li, L., Li, M., Liu, H. et al. Transcription factor, E4BP4, inhibits autophagy and apoptosis in multiple myeloma and promotes the HDAC3-mediated suppression of the Beclin1 promoter to reduce dexamethasone sensitivity. J Transl Med 24, 806 (2026). https://doi.org/10.1186/s12967-026-08345-1  June 22, 2026.  

Overview

Researchers investigated the role of the transcription factor E4BP4 in multiple myeloma progression and drug resistance. The study found that E4BP4 promoted myeloma cell survival by suppressing autophagy and apoptosis and reduced sensitivity to dexamethasone, suggesting that targeting E4BP4 could help overcome treatment resistance.
 

"Anaemia in multiple myeloma: evolving insights into bone marrow microenvironment-driven pathogenesis and targeted management"

Source

Li, P., Xie, H., Ji, Y. et al. Anaemia in multiple myeloma: evolving insights into bone marrow microenvironment-driven pathogenesis and targeted management. Eur J Med Res (2026). https://doi.org/10.1186/s40001-026-04770-6 June 22, 2026.   

Overview

Researchers reviewed the mechanisms underlying anemia in multiple myeloma and evaluated emerging treatment strategies based on disease biology. The review highlights how disruption of the bone marrow microenvironment contributes to anemia and proposes biomarker-driven, targeted approaches that address both the underlying myeloma and the specific pathways impairing red blood cell production.
 

"Efficiency of Automated and Manual Plasma Cell Immunoselection for FISH Analysis in Multiple Myeloma"

Source

H. Podgornik and K. Reberšek, “Efficiency of Automated and Manual Plasma Cell Immunoselection for FISH Analysis in Multiple Myeloma,” International Journal of Laboratory Hematology (2026): 1–8, https://doi.org/10.1111/ijlh.70173.  June 22, 2026.    

Overview

Researchers evaluated whether automated plasma cell immunoselection improves the accuracy of fluorescence in situ hybridization (FISH) testing in multiple myeloma. The study found that automated processing increased plasma cell yield and FISH success rates, enabling more comprehensive cytogenetic testing and supporting more reliable risk stratification, particularly in samples with low bone marrow plasma cell infiltration.
 

"Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma"

Source

van der Weg, K., Bertschinger, M., Bacher, U., Hoffmann, M., Nilius, H., Seipel, K., & Pabst, T. (2026). Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma. Cancers, 18(13), 2032. https://doi.org/10.3390/cancers18132032  June 22, 2026.

Overview

Researchers investigated whether PPM1D mutations associated with clonal hematopoiesis affect outcomes after BCMA-directed CAR T-cell therapy in patients with relapsed or refractory multiple myeloma. The study found that although patients with PPM1D mutations achieved similar initial response rates, they experienced shorter progression-free survival and higher rates of treatment-related toxicity, suggesting these mutations may be a biomarker of less durable CAR T-cell responses.
 

"Advances in Modeling Multiple Myeloma Within the Bone Marrow Tumor Microenvironment for Exploration of Current and Emerging Therapies"

Source

Toomes, C. E. J., Best, O. G., Hollenberg, T., Turner, R., Bonder, C. S., & McClure, B. J. (2026). Advances in Modeling Multiple Myeloma Within the Bone Marrow Tumor Microenvironment for Exploration of Current and Emerging Therapies. Cancers, 18(13), 2050. https://doi.org/10.3390/cancers18132050  June 23, 2026. 

Overview

Researchers reviewed current and emerging preclinical models designed to better replicate the multiple myeloma bone marrow microenvironment, with a particular focus on advanced three-dimensional (3D) culture systems, microfluidics, and organ-on-a-chip technologies. The review concludes that these physiologically relevant models may improve the study of myeloma biology, drug resistance, and precision medicine while reducing reliance on animal models and accelerating the development of more effective therapies. 
 

"A Phase I Trial of Iopofosine I 131 and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma"

Source

Ailawadhi, S., Peterson, J. L., Oliver, K., Longcor, J., & Callander, N. (2026). A Phase I Trial of Iopofosine I 131 and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Cancers, 18(13), 2044. https://doi.org/10.3390/cancers18132044  June 23, 2026. 

Overview

Researchers evaluated the safety and preliminary effectiveness of iopofosine I-131, a targeted radiopharmaceutical, in heavily pretreated patients with relapsed or refractory multiple myeloma. The phase 1 study found that iopofosine had a manageable safety profile with encouraging early antimyeloma activity, supporting further clinical development and evaluation in combination with other therapies. 

 

"Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65–69 Years (CAREMM-2110 study)"

Source

Jung Yeon Lee, Seungpil Jung, Sung-Soo Park, Seonggyu Byeon, Seung-Hwan Shin, Young-Woo Jeon, Seung-Ah Yahng, Suein Choi, Jin Seok Kim, Chang-Ki Min, Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65–69 Years (CAREMM-2110 study), Value in Health, 2026, ISSN 1098-3015, https://doi.org/10.1016/j.jval.2026.05.013. June 22, 2026. 

Overview

Researchers evaluated whether upfront autologous stem cell transplantation is a cost-effective treatment strategy for patients aged 65–69 years with newly diagnosed multiple myeloma. The study found that ASCT improved survival and quality-adjusted life-years at an acceptable additional cost, supporting transplant eligibility based on patient fitness rather than age alone.
 

"Advances in Modeling Multiple Myeloma Within the Bone Marrow Tumor Microenvironment for Exploration of Current and Emerging Therapies"

Source

Toomes, C. E. J., Best, O. G., Hollenberg, T., Turner, R., Bonder, C. S., & McClure, B. J. (2026). Advances in Modeling Multiple Myeloma Within the Bone Marrow Tumor Microenvironment for Exploration of Current and Emerging Therapies. Cancers, 18(13), 2050. https://doi.org/10.3390/cancers18132050  June 23, 2026. 

Overview

Researchers reviewed current and emerging preclinical models that better replicate the multiple myeloma bone marrow microenvironment, focusing on advanced three-dimensional (3D) culture systems, microfluidics, and organ-on-a-chip technologies. The review highlights how these models can improve the study of myeloma biology, drug resistance, biomarker discovery, and precision medicine while providing more physiologically relevant alternatives to traditional two-dimensional cell cultures and animal models for testing new therapies. 

 

"Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma"

Source

Yohannan, B., Langworthy, B.W., Turner, L.E. et al. Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01537-4  June 23, 2026.  

Overview

Researchers examined the incidence and risk factors for second hematologic malignancies after autologous stem cell transplantation in patients with multiple myeloma. The study found that these secondary blood cancers have become more common in the era of novel therapies and were associated with several treatment-related factors, underscoring the importance of long-term monitoring and strategies to reduce risk as patient survival continues to improve.

 

"Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response"

Source

Cenzano, I., Cócera, M., Larrayoz, M. et al. Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74389-y  June 23, 2026. 

Overview

Researchers investigated how the non-immune bone marrow microenvironment changes as monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma. The study identified early alterations in endothelial and mesenchymal stem cells, including an interferon-driven program that could be reversed with standard myeloma therapy, suggesting these changes may represent potential therapeutic targets for slowing disease progression.

 

"Efficacy of exercise interventions in multiple myeloma: a systematic review and meta-analysis"

Source

Polo-Ferrero, L., Martín-Vallejo, J., Mateos-Manteca, M.V. et al. Efficacy of exercise interventions in multiple myeloma: a systematic review and meta-analysis. J Cancer Surviv (2026). https://doi.org/10.1007/s11764-026-02056-8  June 23, 2026.  

Overview

Researchers evaluated the effects of structured exercise programs on physical function and quality of life in adults with multiple myeloma by analyzing results from published clinical studies. The review found that exercise appears to be safe and feasible for patients with multiple myeloma, but current evidence does not demonstrate significant improvements in physical function, fatigue, pain, or quality of life, highlighting the need for larger, higher-quality clinical trials.

 

"Dorsal spinal instrumentation in multiple myeloma: postoperative acute kidney injury is associated with mortality, morbidity, and deterioration of bone and muscle status"

Source

Kylies, J., Leonhardt, LG., Brauneck, E. et al. Dorsal spinal instrumentation in multiple myeloma: postoperative acute kidney injury is associated with mortality, morbidity, and deterioration of bone and muscle status. Eur Spine J (2026). https://doi.org/10.1007/s00586-026-10135-8  June 23, 2026.   

Overview

Researchers examined the impact of postoperative acute kidney injury (AKI) in patients with multiple myeloma undergoing spinal surgery for malignant bone disease. The study found that AKI was associated with shorter survival, higher rates of surgical complications, longer hospital stays, and greater loss of muscle mass, fat, and bone density, highlighting the importance of kidney-protective strategies and multidisciplinary supportive care in this high-risk population.

 

"A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement"

Source

Kenneth J. C. Lim, Maximilian Steinhardt, Matthew J. Rees, Patricia Greipp, Katalin Kelemen, Angela Dispenzieri, Dragan Jevremovic, Linda Baughn, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Prashant Kapoor, Eli Muchtar, Nelson Leung, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Rahma Warsame, Taxiarchis V. Kourelis, Joselle Cook, Moritz Binder, Nadine Abdallah, Saurabh Zanwar, Yi Lin, Ronald S. Go, Mustaqeem A. Siddiqui, Ricardo D. Parrondo, Sikander Ailawadi, Vivek Roy, Rachel Cooke, Karen Dun, Adrian Zordan, Slavisa Ninkovic, Sharene H. Best, Gabriela A. Alatorre, J. E. Wiedmeier-Nutor, K. Martin Kortum, Hermann Einsele, Saurabh Chhabra, P. Leif Bergsagel, Robert A. Kyle, Morie A. Gertz, Shaji K. Kumar, S. Vincent Rajkumar, Rafael Fonseca, Wilson I. Gonsalves, Udit Yadav; A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement. Blood Adv 2026; 10 (12): 4286–4295. doi: https://doi.org/10.1182/bloodadvances.2025019136  June 23, 2026. 

Overview

Researchers compared outcomes after radiation therapy in patients with solitary bone plasmacytoma (SBP) and solitary bone plasmacytoma with minimal marrow involvement (SBPmm). The study found that patients with SBPmm had a substantially higher risk of early progression to multiple myeloma than those with SBP, suggesting they may benefit from prospective studies evaluating upfront systemic therapy in addition to radiation.

 

"BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study"

Source

Jin Liu, Xiaoqiang Fan, Liying Peng, Jia Liu, Haiyan He, Wanting Qiang, Lina Jin, Lang Shi, Jing Lu, Pei Guo, Nina Shah, Qi Zhang, Lianjun Shen, Juan Du; BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study. Blood Adv 2026; 10 (12): 4134–4143. doi: https://doi.org/10.1182/bloodadvances.2025019036  June 23, 2026. 

Overview

Researchers evaluated AZD0120, a dual-targeting BCMA/CD19 CAR T-cell therapy, as frontline treatment for transplant-ineligible patients aged 70 years and older with newly diagnosed multiple myeloma. In this early phase study, the therapy produced deep responses, with all patients achieving stringent complete response and MRD negativity, while demonstrating a manageable safety profile, supporting further investigation in older adults.

 

"Identification of Bone Marrow and Peripheral Blood Plasma Extracellular Vesicle Protein Biomarker Signatures for Multiple Myeloma Diagnosis and Staging"

Source

Cheryl A, Sheridan R, Brennan K, Bazou D, Matallanas D, O’Gorman P, Iglesias-Martinez LF, Mc Gee MM. Identification of Bone Marrow and Peripheral Blood Plasma Extracellular Vesicle Protein Biomarker Signatures for Multiple Myeloma Diagnosis and Staging. Int J Nanomedicine. 2026 Jun 23;21:576858. doi: 10.2147/IJN.S576858. 

Overview

Researchers investigated whether proteins carried by extracellular vesicles (EVs) in blood could serve as a non-invasive liquid biopsy for diagnosing and monitoring multiple myeloma. Using proteomics and machine learning, they identified a six-protein biomarker signature that accurately distinguished disease stages, supporting the potential of EV-based blood tests as an alternative to invasive bone marrow biopsies pending further validation.

 

"An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma"

Source

Praveen Kumar Tiwari, Bomin Ku, Drew A. Harrison, Sarah Rizvi, Samuel Ojeda, Jessica Duffy, Leonie Cluse, Jennifer R. Devlin, Nenad Bartonicek, Olga Motorna, Ann-Sophie Koglin, Barbara Karakyriakou, Kaitlyn Gagnon, Ramya S. Iyer, Regina Egan, Pat Greninger, Lauren Benz, Caroline Greco, Julia Norton, Amruth Kumar, Eric F. Zaniewski, Soroush Hajizadeh, Robert Morris, Genna Mullen, Ajinkya S. Kawale, Sangwon Min, Sai Reddy Doda, Raghu Vannam, Lee Zou, Wilhelm Haas, Abner Louissaint, Ricky W. Johnstone, Christopher J. Ott, An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma, Cell Reports, Volume 45, Issue 6, 2026, 117464, ISSN 2211-1247, https://doi.org/10.1016/j.celrep.2026.117464. June 23, 2026.  

Overview

Researchers investigated whether proteins carried by extracellular vesicles (EVs) in blood could serve as a non-invasive liquid biopsy for diagnosing and monitoring multiple myeloma. Using proteomics and machine learning, they identified a six-protein biomarker signature that accurately distinguished disease stages, supporting the potential of EV-based blood tests as an alternative to invasive bone marrow biopsies pending further validation.

 

"Advancements in multiple myeloma treatment: Integrating quadruplet and dual antigen CAR-T therapy"

Source

Mahnoor Khan, Dominic Alfano, Anisha Gupta, Advancements in multiple myeloma treatment: Integrating quadruplet and dual antigen CAR-T therapy, iScience, 2026, 116509, ISSN 2589-0042, https://doi.org/10.1016/j.isci.2026.116509. June 24, 2026.  

Overview

Researchers reviewed the evolution of CAR T-cell therapy for multiple myeloma, highlighting recent advances such as earlier-line use, dual-target CAR T-cell designs, and combination strategies with quadruplet therapy to improve treatment durability and reduce relapse. The review also discusses current challenges—including toxicity, manufacturing, and access—and outlines future directions aimed at making CAR T-cell therapy more effective, personalized, and widely available. 

 

"Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65–75 years: a real-world study"

Source

Lee, N., Kim, S., Lee, Y. et al. Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65–75 years: a real-world study. Blood Res. (2026). https://doi.org/10.1007/s44313-026-00149-y June 24, 2026.   

Overview

Researchers evaluated real-world outcomes of autologous stem cell transplantation (ASCT) and quadruplet therapy in patients aged 65–75 years with newly diagnosed multiple myeloma. The study found that ASCT significantly improved survival in selected patients aged 65–69 years, while quadruplet therapy provided substantial benefit for patients aged 70–75 years and those not undergoing transplant, supporting fitness-based rather than age-based treatment decisions.

 

"Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients"

Source

van de Donk, N.W.C.J., Schjesvold, F., van der Holt, B. et al. Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients. Blood Cancer J. 16, 102 (2026). https://doi.org/10.1038/s41408-026-01549-0  June 24, 2026.   

Overview

Researchers reported long-term outcomes from a phase 2 study evaluating carfilzomib-, lenalidomide-, and dexamethasone (KRd)-based therapy with autologous stem cell transplantation (ASCT) in patients with newly diagnosed primary plasma cell leukemia (pPCL). The study found that continuous KRd-based treatment improved disease control compared with historical outcomes, although survival remained poor—particularly in patients with high-risk cytogenetic abnormalities or elevated LDH—highlighting the need to incorporate newer immunotherapies into frontline treatment. 

 

"Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement"

Source

Alexander Xiao, Saurabh S. Zanwar, Yi Lin, Prashant Kapoor, Nadine Abdallah, Francis Baudi, Moritz Binder, Angela Dispenzieri, David Dingli, Morie A Gertz, Wilson I Gonsalves, Suzanne R Hayman, Taxiarchis V. Kourelis, Nelson Leung, Eli Muchtar, Mustaqeem Siddiqui, Melinda SY Tan, Rahma Warsame, S Vincent Rajkumar, Shaji K Kumar; Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement. Blood Adv 2026; bloodadvances.2026020668. doi: https://doi.org/10.1182/bloodadvances.2026020668  June 24, 2026.   

Overview

Researchers evaluated the characteristics and outcomes of central nervous system multiple myeloma (CNS-MM), a rare form of extramedullary disease, in patients treated over two decades. The study found that CNS-MM was associated with high-risk disease and very poor survival, but patients treated with CAR T-cell therapy or bispecific antibodies lived substantially longer than those who did not receive these therapies, supporting further study of immune-based treatments for this aggressive complication.

 

"Efficacy of Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma With Extramedullary Disease: A Systematic Review and Meta-Analysis"

Source

Burke O J, Peruzzo N, Tul Ain Khan N, et al. (June 24, 2026) Efficacy of Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma With Extramedullary Disease: A Systematic Review and Meta-Analysis. Cureus 18(6): e111438. doi:10.7759/cureus.111438 June 24, 2026.  

Overview

Researchers conducted a systematic review and meta-analysis to evaluate how well BCMA- and GPRC5D-targeted bispecific antibodies work in patients with relapsed or refractory multiple myeloma and baseline extramedullary disease (EMD). The analysis found that these therapies produced objective responses in approximately 45% of patients with EMD, providing an important benchmark for this high-risk population while highlighting the need for combination strategies to further improve outcomes.

 

"IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma"

Source

Nahia Gómez-Echarte, Arantxa Carrasco-León, Alba Maiqués-Díaz, Naroa Barrena, Estibaliz Miranda, Leire Garate, Ane Amundarain, Patxi San Martín-Uriz, Stella Charalampopoulou, Luis Vitores Valcárcel, Beñat Ariceta, Paula Rodriguez-Marquez, Juan Roberto Rodriguez-Madoz, Kazuya Ishiguro, Francisco J. Planes, Paula Rodriguez-Otero, Constantine S. Mitsiades, José Ignacio Martín-Subero, Edurne San José-Enériz, Felipe Prosper, Xabier Agirre; IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma. Blood 2026; 147 (26): 3195–3208. doi: https://doi.org/10.1182/blood.2025029422  June 25, 2026. 

Overview

Researchers identified IRF2 as a previously underrecognized transcription factor that plays a key role in the development and progression of multiple myeloma using CRISPR gene-editing and genomic analyses. The study found that IRF2 promotes myeloma cell survival and migration, is active in early precursor conditions such as MGUS and smoldering myeloma, and is associated with poorer survival, suggesting it could serve as a promising new therapeutic target.

 

"Bidirectional relationship between the systemic immune-inflammation index and post-autologous stem cell transplantation anemia in multiple myeloma: a retrospective cohort study"

Source

Liu, L., Ruan, M., Wang, M. et al. Bidirectional relationship between the systemic immune-inflammation index and post-autologous stem cell transplantation anemia in multiple myeloma: a retrospective cohort study. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-16414-3  June 25, 2026. 

Overview

Researchers investigated whether the systemic immune-inflammation index (SII), a blood-based marker of inflammation, could predict anemia after autologous stem cell transplantation (ASCT) in patients with multiple myeloma. The study found that patients with high pre-transplant SII were more likely to develop post-transplant anemia, experience more severe anemia, and recover more slowly, suggesting that SII may help identify patients who could benefit from closer monitoring and supportive care.

 

"Toxicities of CAR-T, Bispecific Antibodies, and Antibody–Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management"

Source

Hej-Ali, S., Banwell, K., Mohamed, H., Cervi, A., Dass, A., Gupta, R., Hamm, C., Kanjeekal, S., Strange Seguel, I., Szalay, M., & Khan, S. (2026). Toxicities of CAR-T, Bispecific Antibodies, and Antibody–Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management. Cancers, 18(13), 2083. https://doi.org/10.3390/cancers18132083  June 25, 2026.

Overview

Researchers reviewed the full spectrum of toxicities associated with BCMA- and GPRC5D-directed immunotherapies for relapsed or refractory multiple myeloma, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates. The review emphasizes practical strategies for patient selection, risk stratification, toxicity recognition, and long-term monitoring, highlighting that these therapies can be delivered safely in community settings when supported by appropriate infrastructure and multidisciplinary care.
 

"Ruxolitinib inhibits CaMKII-γ to reverse bortezomib resistance in multiple myeloma"

Source

Liang, R., Liu, H., Zhong, X. et al. Ruxolitinib inhibits CaMKII-γ to reverse bortezomib resistance in multiple myeloma. Commun Biol (2026). https://doi.org/10.1038/s42003-026-10553-w June 25, 2026. 

Overview

Researchers identified calcium/calmodulin-dependent protein kinase II gamma (CaMKII-γ) as a key driver of bortezomib resistance in multiple myeloma through activation of the AMPK-ULK1 autophagy pathway. The study also found that the JAK inhibitor ruxolitinib selectively inhibited CaMKII-γ and restored bortezomib sensitivity in laboratory and animal models, suggesting a potential new strategy for overcoming drug resistance in multiple myeloma.
 

"Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial"

Source

Raab, M.S., Weinhold, N., Kortüm, K.M. et al. Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04471-x  June 25, 2026. 

Overview

Researchers evaluated frontline teclistamab combined with daratumumab and lenalidomide, with or without bortezomib, in transplant-eligible patients with newly diagnosed multiple myeloma. The phase 2 study demonstrated a manageable safety profile, a 100% overall response rate, and exceptionally high minimal residual disease (MRD)-negative complete response rates before maintenance therapy, supporting this immunotherapy-based regimen as a promising frontline treatment strategy. 

 

"Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data"

Source

Kostiou, V., Chelliah, V., van der Graaf, P.H., Kierzek, A.M., Farzana, T., Mailankody, S. and Jurgens, E.M. (2026), Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.70378  June 27, 2026. 

Overview

Researchers developed a quantitative systems pharmacology (QSP) model to predict treatment response and relapse after CAR T-cell therapy in relapsed or refractory multiple myeloma. The model identified high disease burden, low target antigen expression, and reduced CAR T-cell activity as key drivers of poor outcomes, and predicted that sequential GPRC5D-targeted CAR T-cell therapy followed by BCMA-targeted CAR T-cell therapy may improve treatment responses.

 

"Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma"

Source

X. Si, R. Zhao, Y. Song, et al., “Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma,” Hematological Oncology (2026): e70216, https://doi.org/10.1002/hon.70216.  June 27, 2026.  

Overview

Researchers characterized IgA glycosylation patterns in multiple myeloma and identified increased fucosylation as a distinguishing feature of the disease. The study found that the enzyme FUT8 promotes myeloma cell growth and spread through Wnt/β-catenin signaling, while loss of IgA fucosylation was associated with deep treatment responses, suggesting FUT8 may serve as both a biomarker and a potential therapeutic target.

 

"Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World Study"

Source

Kars, T. U., Göker, H., Demiroğlu, H., Malkan, Ü. Y., Aladağ Karakulak, E., Erdekli, F. T., Deveci, B., Yiğit Kaya, S., Kaynar, L., Dikyar, A., Şahin, S. E., Bağcı, M., Sağlam, B., Güneş, A. K., Sevindik, Ö. G., & Karakuş, V. (2026). Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World Study. Journal of Clinical Medicine, 15(13), 5045. https://doi.org/10.3390/jcm15135045  June 27, 2026.   

Overview

Researchers evaluated whether patients with relapsed multiple myeloma benefit from receiving re-induction chemotherapy before a second autologous stem cell transplant (ASCT2) or proceeding directly to transplant. In this real-world multicenter study, re-induction chemotherapy did not improve progression-free survival after ASCT2, and differences in overall survival were no longer significant after adjusting for patient characteristics, suggesting that treatment selection rather than sequencing likely influenced outcomes. The findings support ASCT2 as an effective salvage option while highlighting the need for prospective studies to determine the optimal timing of re-induction therapy. 

 

"Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis"

Source

Kitsada Wudhikarn, Lohith Gowda, Qiran Ye, Temitope Oloyede, Michael Martens, Rahul Banerjee, Srinivas S. Devarakonda, Hongtao Liu, Megan M. Herr, Jo-Anne H. Young, Tania Jain, Ajoy Dias, Taiga Nishihori, Abu-Sayeef Mirza, Siddhartha Ganguly, Amer M. Beitinjaneh, Mahmoud Aljurf, Baldeep Wirk, Nosha Farhadfar, Yvonne A. Efebera, Miguel-Angel Perales, Christen L. Ebens, Hemant S Murthy, Joshua A. Hill, Christopher E. Dandoy, Sanghee Hong, Zeinab El Boghdadly, Othman Salim Akhtar, Jeffery J. Auletta, Anna R. Huppler, Muhammad Bilal Abid, Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis, Transplantation and Cellular Therapy, 2026, ISSN 2666-6367, https://doi.org/10.1016/j.jtct.2026.06.029. June 27, 2026. 

Overview

Researchers analyzed real-world outcomes in 807 patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel (ide-cel) to better understand infection risk after BCMA-directed CAR T-cell therapy. Infections were common during the first 100 days, with bacterial infections occurring early and viral infections becoming more frequent later. Patients with prior infections, poor performance status, severe cytokine release syndrome or neurotoxicity, recurrent infections, or early relapse had worse survival. The findings emphasize the importance of identifying high-risk patients and implementing close monitoring and infection prevention strategies following ide-cel treatment.

 

"IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment"

Source

Rajeeve, S., Nagar, S.P., Ghosh, S. et al. IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment. Oncol Ther (2026). https://doi.org/10.1007/s40487-026-00455-6  June 28, 2026.  

Overview

Researchers evaluated real-world outcomes of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed or refractory multiple myeloma after one to three prior lines of therapy. The study found exceptionally high response and minimal residual disease (MRD)-negative rates across a range of bridging therapies, with most patients remaining progression-free and alive during early follow-up, supporting the effectiveness of earlier use of cilta-cel and its potential to achieve durable, treatment-free remission.
 

"A Scalable Lentiviral Workflow for Laboratory-Scale Generation of BCMA/GPRC5D Co-Transduced CAR-T Cells in Multiple Myeloma"

Source

Nowak, E., Morawiec, E., Pudełko, A., Polak, A., Broncel, M., Matczyńska, D., Zamojski, D., Czerwinski, M., & Bednarska-Czerwińska, A. (2026). A Scalable Lentiviral Workflow for Laboratory-Scale Generation of BCMA/GPRC5D Co-Transduced CAR-T Cells in Multiple Myeloma. Current Issues in Molecular Biology, 48(7), 679. https://doi.org/10.3390/cimb48070679  June 29, 2026. 

Overview

Researchers optimized lentiviral vector production and T-cell transduction methods to improve the manufacturing of BCMA- and GPRC5D-targeted CAR T-cell therapies for multiple myeloma. The optimized workflow produced higher viral yields, improved gene transfer efficiency, and successfully generated dual-targeting CAR T cells, providing a reproducible platform to support future preclinical and early-stage clinical development.

 

"Humanized biparatopic nanobody-based CAR-T cells overcome antigen-heterogeneity in multiple myeloma"

Source

Zhou, J., Wu, K., Lei, B. et al. Humanized biparatopic nanobody-based CAR-T cells overcome antigen-heterogeneity in multiple myeloma. J Transl Med (2026). https://doi.org/10.1186/s12967-026-08533-z  June 29, 2026.  

Overview

Researchers developed and tested a next-generation biparatopic BCMA-targeted CAR T-cell therapy designed to overcome common causes of relapse in multiple myeloma, including low BCMA expression and interference from soluble BCMA. In preclinical models, the engineered CAR T cells demonstrated stronger and more durable antitumor activity, reduced T-cell exhaustion, and sustained function under challenging conditions, supporting further clinical evaluation of this approach.

 

"NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma"

Source

Bo Hu, Jacob Edwards, Hardik Modi, Jim Gamez, Oscar Enrique Echeagaray, Kyle Hess, Yue Ren, Diana Anderson, Marta Larrayoz, Jinyi Zhu, Scott Arne Johnson, Gauri Deb, Diana Jankeel, Preethi Janardhanan, Jim Leisten, Sophie Peng, Andy Christoforou, Nicholas Stong, Celia Fontanillo, Chad C Bjorklund, Patrick Ryan Hagner, Anita Krithivas Gandhi, Jose A Martínez-Climent, Rama Krishna Narla, Antonia Lopez-Girona, Mark Rolfe, Neil Bence, Deborah S Mortensen, Lynda Groocock; NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma. Blood 2026; blood.2025031998. doi: https://doi.org/10.1182/blood.2025031998  June 29, 2026. 

Overview

Researchers developed a targeted protein degrader that selectively eliminates NSD2, a protein overexpressed in patients with high-risk t(4;14) multiple myeloma. In preclinical models, NSD2 degradation reversed key cancer-driving gene programs, disrupted the tumor-supportive bone marrow microenvironment, and prolonged survival, supporting NSD2 as a promising therapeutic target for this genetically defined subgroup of patients.

 

"Flow Cytometric MRD Analysis and Survival in Multiple Myeloma: A Single-Center Real-Life Cohort Study"

Source

Akar, E., Çakmak, Ş., Baysal, M. et al. Flow Cytometric MRD Analysis and Survival in Multiple Myeloma: A Single-Center Real-Life Cohort Study. Indian J Hematol Blood Transfus (2026). https://doi.org/10.1007/s12288-026-02460-1  June 29, 2026. 

Overview

Researchers evaluated the real-world prognostic value of measurable residual disease (MRD) testing using conventional multiparametric flow cytometry after first-line therapy and autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma. The study found that patients who were MRD-negative after ASCT experienced significantly longer progression-free and overall survival, demonstrating that widely available flow cytometry-based MRD testing can provide meaningful prognostic information even in resource-limited settings.

 

"Single-nuclei UPR profiling by flow cytometry reveals bortezomib resistance mechanisms in multiple myeloma"

Source

Gigan, J.P., Garcia-Gonzalez, P., Pilotti, A. et al. Single-nuclei UPR profiling by flow cytometry reveals bortezomib resistance mechanisms in multiple myeloma. EMBO Mol Med (2026). https://doi.org/10.1038/s44321-026-00469-7  June 29, 2026 

Overview

Researchers developed a new flow cytometry method, called SNUPR, to measure activation of the unfolded protein response (UPR) in cancer cells and investigated its role in multiple myeloma. The study found that activation of the IRE1α pathway is essential for the development of bortezomib resistance and is associated with poorer patient outcomes, suggesting that targeting IRE1α may help overcome proteasome inhibitor resistance in multiple myeloma.


 

"Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy"

Source

Janakiram M, Ghosh S, Alegria V, Perciavalle M, Emond B, Maitland J, Bixby T, Nagar SP, Qureshi ZP, Bakaloudi DR, Dima D. Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy. J Comp Eff Res. 2026 Jun 29:e260052. doi: 10.57264/cer-2026-0052. 

Overview

Researchers developed a new flow cytometry method, called SNUPR, to measure activation of the unfolded protein response (UPR) in cancer cells and investigated its role in multiple myeloma. The study found that activation of the IRE1α pathway is essential for the development of bortezomib resistance and is associated with poorer patient outcomes, suggesting that targeting IRE1α may help overcome proteasome inhibitor resistance in multiple myeloma.


 

"Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma"

Source

Ali, Hafsa MBBSa; Hilal, Hiba MBBSb; Gul, Maliha MBBSc; Asad, Maham MBBSb; Jaber Amin, Mohammed Hammad MBBSd,*. Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. Annals of Medicine & Surgery 88(6):p 3022-3023, June 2026. | DOI: 10.1097/MS9.0000000000004952 June 2026. 

Overview

Researchers reviewed the preclinical and early clinical evidence for forimtamig, a next-generation GPRC5D-targeted bispecific antibody for relapsed or refractory multiple myeloma. The review highlights how its novel 2:1 binding design enhances T-cell activation and tumor cell killing, including against tumors with low GPRC5D expression, and discusses its potential to improve the depth and durability of responses, particularly in combination with existing myeloma therapies.

 

"Performance of Free Light Chain reagents in the Dutch External Quality Assessment programme over the past 14 years"

Source

Moniek M. Bioch, Corrie M. de Kat Angelino, Anke J. ten Haaken-Meijer, Marc H.M. Thelen, Joannes F.M. Jacobs, Performance of Free Light Chain reagents in the Dutch External Quality Assessment programme over the past 14 years, Clinica Chimica Acta, 2026, 121213, ISSN 0009-8981, https://doi.org/10.1016/j.cca.2026.121213. June 30, 2026. 

Overview

Researchers evaluated the long-term performance of two commonly used serum free light chain (sFLC) assays across 37 laboratories participating in the Dutch external quality assessment program. The study found good precision within each assay but significant differences between the two testing methods, highlighting the need for assay-specific interpretation and greater standardization before universal diagnostic, prognostic, or treatment response criteria can be applied across laboratories.

 

"Performance of Free Light Chain reagents in the Dutch External Quality Assessment programme over the past 14 years"

Source

Zayad, A., Younis, O., Awadallah, C., Kamboj, I., Mohammed, A., Shatnawi, A. E., Ali, A., Alzatary, H., Khan, A. M., Shaikh, H., Alkharabsheh, O., Shah, M. R., Mewawalla, P., McGuirk, J. P., Mahmoudjafari, Z., Mushtaq, M. U., Kort, J., Habib, A., Atrash, S., & Abdallah, A.-O. (2026). The ClinicalTrials.gov Landscape of Multiple Myeloma Clinical Trials: A 20-Year Analysis of Geographic Distribution and Growth Patterns: USMIRC Analysis. Current Oncology, 33(7), 396. https://doi.org/10.3390/curroncol33070396  June 30, 2026.  

Overview

Researchers analyzed global trends in multiple myeloma clinical trials over the past two decades using data from ClinicalTrials.gov. The study found that while trial activity has expanded worldwide, it remains heavily concentrated in the United States and other high-income countries, highlighting the need to expand clinical trial infrastructure and international collaboration to improve access to research in underrepresented regions.

 

"The ClinicalTrials.gov Landscape of Multiple Myeloma Clinical Trials: A 20-Year Analysis of Geographic Distribution and Growth Patterns: USMIRC Analysis"

Source

Zayad, A., Younis, O., Awadallah, C., Kamboj, I., Mohammed, A., Shatnawi, A. E., Ali, A., Alzatary, H., Khan, A. M., Shaikh, H., Alkharabsheh, O., Shah, M. R., Mewawalla, P., McGuirk, J. P., Mahmoudjafari, Z., Mushtaq, M. U., Kort, J., Habib, A., Atrash, S., & Abdallah, A.-O. (2026). The ClinicalTrials.gov Landscape of Multiple Myeloma Clinical Trials: A 20-Year Analysis of Geographic Distribution and Growth Patterns: USMIRC Analysis. Current Oncology, 33(7), 396. https://doi.org/10.3390/curroncol33070396  June 30, 2026.  

Overview

Researchers analyzed global trends in multiple myeloma clinical trials over the past two decades using data from ClinicalTrials.gov. The study found that while trial activity has expanded worldwide, it remains heavily concentrated in the United States and other high-income countries, highlighting the need to expand clinical trial infrastructure and international collaboration to improve access to research in underrepresented regions.

 

"Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma"

Source

Nicholas Eardley Bingham, Julie R Boiko, Daniel C Jones, Daniel Wong, Tiffany Khong, Sridurga Mithraprabhu, Kathleen S. Ensbey, Anna E Elz, Evan W. Newell, Andrew Spencer, Geoffrey R Hill; Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma. Blood Adv 2026; bloodadvances.2026020500. doi: https://doi.org/10.1182/bloodadvances.2026020500  June 30, 2026.   

Overview

Researchers used spatial transcriptomics to characterize the tumor microenvironment of extramedullary multiple myeloma (EMD), a high-risk form of the disease that develops outside the bone marrow. The study found that EMD tumors are dominated by immunosuppressive macrophages, exhausted T cells, and tumor-associated fibroblasts that create distinct immune-resistant niches supporting myeloma growth, identifying potential microenvironmental targets for future therapies.

 

"A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging"

Source

Gu T, Chen Z, Tang B, Wang T, Yang Q, Liu H, Liang Z, Wang Q, Zhang Y, Sun Y, Di M, Yuan T, Qiu Y, Du Y, Song L, Wu S, Wang W, Xu X, Dong Y, Kang L. A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging. J Clin Invest. 2026 Jun 30:e207391. doi: 10.1172/JCI207391. Epub ahead of print.  June 30, 2026.   

Overview

Researchers evaluated a novel BCMA-targeted PET imaging tracer, ^68Ga-PFBC01, for detecting and monitoring multiple myeloma. The phase 1 study found that ^68Ga-PFBC01 PET/CT was more sensitive than standard ^18F-FDG PET/CT, correlated closely with established markers of disease burden, and influenced treatment decisions, supporting its potential as a more accurate, biologically targeted imaging tool for multiple myeloma.

 

"Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study from China"

Source

W.Li, W.Tian, J.Ma, et al., “Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study from China,” Cancer Medicine15, no. 6 (2026): e71986, https://doi.org/10.1002/cam4.71986. June 2026.    

Overview

Researchers analyzed the clinical features and outcomes of 35 patients with central nervous system multiple myeloma (CNS-MM) across nine centers in China. The study found that CNS involvement most often occurred after relapse, was associated with high-risk disease and poor survival despite multimodal treatment, and underscores the urgent need for more effective therapies, including further evaluation of CAR T-cell therapy and other novel immunotherapies.

 

"Multiple Myeloma With Spinal Involvement: Renal Dysfunction and Albuminuria Are Associated With Progressive Sarcopenia in a Longitudinal CT Morphometric Study"

Source

Julian Kylies, Dominik Kylies, Katja Weisel, Ulrich O. Wenzel, Tobias B. Huber, Lennart Viezens, Leon-Gordian Leonhardt, Multiple Myeloma With Spinal Involvement: Renal Dysfunction and Albuminuria Are Associated With Progressive Sarcopenia in a Longitudinal CT Morphometric Study, Brain and Spine, 2026, 106153, ISSN 2772-5294, https://doi.org/10.1016/j.bas.2026.106153. June 30, 2026. 

Overview

Researchers investigated how kidney dysfunction affects changes in muscle and body composition in patients with multiple myeloma using longitudinal CT imaging. The study found that reduced kidney function, albuminuria, and low serum albumin were associated with accelerated muscle and fat loss and worsening physical function, suggesting these readily available clinical markers may help identify patients who need earlier supportive care and closer monitoring.